<html xmlns:v="urn:schemas-microsoft-com:vml"
xmlns:o="urn:schemas-microsoft-com:office:office"
xmlns:w="urn:schemas-microsoft-com:office:word"
xmlns:m="http://schemas.microsoft.com/office/2004/12/omml"
xmlns="http://www.w3.org/TR/REC-html40">

<head>
<meta http-equiv=Content-Type content="text/html; charset=windows-1252">
<meta name=ProgId content=Word.Document>
<meta name=Generator content="Microsoft Word 15">
<meta name=Originator content="Microsoft Word 15">
<link rel=File-List
href="Statistical%20Results%20Interpretation%20Summary%20Table_files/filelist.xml">
<link rel=Edit-Time-Data
href="Statistical%20Results%20Interpretation%20Summary%20Table_files/editdata.mso">
<!--[if !mso]>
<style>
v\:* {behavior:url(#default#VML);}
o\:* {behavior:url(#default#VML);}
w\:* {behavior:url(#default#VML);}
.shape {behavior:url(#default#VML);}
</style>
<![endif]--><!--[if gte mso 9]><xml>
 <o:DocumentProperties>
  <o:Author>He, Dian (NIH/NICHD) [C]</o:Author>
  <o:Template>Normal</o:Template>
  <o:LastAuthor>He, Dian (NIH/NICHD) [C]</o:LastAuthor>
  <o:Revision>2</o:Revision>
  <o:TotalTime>1746</o:TotalTime>
  <o:Created>2026-02-01T18:09:00Z</o:Created>
  <o:LastSaved>2026-02-01T18:09:00Z</o:LastSaved>
  <o:Pages>1</o:Pages>
  <o:Words>2057</o:Words>
  <o:Characters>11728</o:Characters>
  <o:Company>NICHD</o:Company>
  <o:Lines>97</o:Lines>
  <o:Paragraphs>27</o:Paragraphs>
  <o:CharactersWithSpaces>13758</o:CharactersWithSpaces>
  <o:Version>16.00</o:Version>
 </o:DocumentProperties>
 <o:OfficeDocumentSettings>
  <o:AllowPNG/>
 </o:OfficeDocumentSettings>
</xml><![endif]-->
<link rel=themeData
href="Statistical%20Results%20Interpretation%20Summary%20Table_files/themedata.thmx">
<link rel=colorSchemeMapping
href="Statistical%20Results%20Interpretation%20Summary%20Table_files/colorschememapping.xml">
<!--[if gte mso 9]><xml>
 <w:WordDocument>
  <w:SpellingState>Clean</w:SpellingState>
  <w:GrammarState>Clean</w:GrammarState>
  <w:TrackMoves>false</w:TrackMoves>
  <w:TrackFormatting/>
  <w:PunctuationKerning/>
  <w:ValidateAgainstSchemas/>
  <w:SaveIfXMLInvalid>false</w:SaveIfXMLInvalid>
  <w:IgnoreMixedContent>false</w:IgnoreMixedContent>
  <w:AlwaysShowPlaceholderText>false</w:AlwaysShowPlaceholderText>
  <w:DoNotPromoteQF/>
  <w:LidThemeOther>EN-US</w:LidThemeOther>
  <w:LidThemeAsian>ZH-CN</w:LidThemeAsian>
  <w:LidThemeComplexScript>X-NONE</w:LidThemeComplexScript>
  <w:Compatibility>
   <w:BreakWrappedTables/>
   <w:SnapToGridInCell/>
   <w:WrapTextWithPunct/>
   <w:UseAsianBreakRules/>
   <w:DontGrowAutofit/>
   <w:SplitPgBreakAndParaMark/>
   <w:EnableOpenTypeKerning/>
   <w:DontFlipMirrorIndents/>
   <w:OverrideTableStyleHps/>
   <w:UseFELayout/>
  </w:Compatibility>
  <m:mathPr>
   <m:mathFont m:val="Cambria Math"/>
   <m:brkBin m:val="before"/>
   <m:brkBinSub m:val="&#45;-"/>
   <m:smallFrac m:val="off"/>
   <m:dispDef/>
   <m:lMargin m:val="0"/>
   <m:rMargin m:val="0"/>
   <m:defJc m:val="centerGroup"/>
   <m:wrapIndent m:val="1440"/>
   <m:intLim m:val="subSup"/>
   <m:naryLim m:val="undOvr"/>
  </m:mathPr></w:WordDocument>
</xml><![endif]--><!--[if gte mso 9]><xml>
 <w:LatentStyles DefLockedState="false" DefUnhideWhenUsed="false"
  DefSemiHidden="false" DefQFormat="false" DefPriority="99"
  LatentStyleCount="376">
  <w:LsdException Locked="false" Priority="0" QFormat="true" Name="Normal"/>
  <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 1"/>
  <w:LsdException Locked="false" Priority="9" SemiHidden="true"
   UnhideWhenUsed="true" QFormat="true" Name="heading 2"/>
  <w:LsdException Locked="false" Priority="9" SemiHidden="true"
   UnhideWhenUsed="true" QFormat="true" Name="heading 3"/>
  <w:LsdException Locked="false" Priority="9" SemiHidden="true"
   UnhideWhenUsed="true" QFormat="true" Name="heading 4"/>
  <w:LsdException Locked="false" Priority="9" SemiHidden="true"
   UnhideWhenUsed="true" QFormat="true" Name="heading 5"/>
  <w:LsdException Locked="false" Priority="9" SemiHidden="true"
   UnhideWhenUsed="true" QFormat="true" Name="heading 6"/>
  <w:LsdException Locked="false" Priority="9" SemiHidden="true"
   UnhideWhenUsed="true" QFormat="true" Name="heading 7"/>
  <w:LsdException Locked="false" Priority="9" SemiHidden="true"
   UnhideWhenUsed="true" QFormat="true" Name="heading 8"/>
  <w:LsdException Locked="false" Priority="9" SemiHidden="true"
   UnhideWhenUsed="true" QFormat="true" Name="heading 9"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="index 1"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="index 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="index 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="index 4"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="index 5"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="index 6"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="index 7"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="index 8"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="index 9"/>
  <w:LsdException Locked="false" Priority="39" SemiHidden="true"
   UnhideWhenUsed="true" Name="toc 1"/>
  <w:LsdException Locked="false" Priority="39" SemiHidden="true"
   UnhideWhenUsed="true" Name="toc 2"/>
  <w:LsdException Locked="false" Priority="39" SemiHidden="true"
   UnhideWhenUsed="true" Name="toc 3"/>
  <w:LsdException Locked="false" Priority="39" SemiHidden="true"
   UnhideWhenUsed="true" Name="toc 4"/>
  <w:LsdException Locked="false" Priority="39" SemiHidden="true"
   UnhideWhenUsed="true" Name="toc 5"/>
  <w:LsdException Locked="false" Priority="39" SemiHidden="true"
   UnhideWhenUsed="true" Name="toc 6"/>
  <w:LsdException Locked="false" Priority="39" SemiHidden="true"
   UnhideWhenUsed="true" Name="toc 7"/>
  <w:LsdException Locked="false" Priority="39" SemiHidden="true"
   UnhideWhenUsed="true" Name="toc 8"/>
  <w:LsdException Locked="false" Priority="39" SemiHidden="true"
   UnhideWhenUsed="true" Name="toc 9"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Normal Indent"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="footnote text"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="annotation text"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="header"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="footer"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="index heading"/>
  <w:LsdException Locked="false" Priority="35" SemiHidden="true"
   UnhideWhenUsed="true" QFormat="true" Name="caption"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="table of figures"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="envelope address"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="envelope return"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="footnote reference"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="annotation reference"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="line number"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="page number"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="endnote reference"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="endnote text"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="table of authorities"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="macro"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="toa heading"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List Bullet"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List Number"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List 4"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List 5"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List Bullet 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List Bullet 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List Bullet 4"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List Bullet 5"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List Number 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List Number 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List Number 4"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List Number 5"/>
  <w:LsdException Locked="false" Priority="10" QFormat="true" Name="Title"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Closing"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Signature"/>
  <w:LsdException Locked="false" Priority="1" SemiHidden="true"
   UnhideWhenUsed="true" Name="Default Paragraph Font"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Body Text"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Body Text Indent"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List Continue"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List Continue 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List Continue 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List Continue 4"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List Continue 5"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Message Header"/>
  <w:LsdException Locked="false" Priority="11" QFormat="true" Name="Subtitle"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Salutation"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Date"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Body Text First Indent"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Body Text First Indent 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Note Heading"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Body Text 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Body Text 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Body Text Indent 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Body Text Indent 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Block Text"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Hyperlink"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="FollowedHyperlink"/>
  <w:LsdException Locked="false" Priority="22" QFormat="true" Name="Strong"/>
  <w:LsdException Locked="false" Priority="20" QFormat="true" Name="Emphasis"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Document Map"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Plain Text"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="E-mail Signature"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="HTML Top of Form"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="HTML Bottom of Form"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Normal (Web)"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="HTML Acronym"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="HTML Address"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="HTML Cite"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="HTML Code"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="HTML Definition"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="HTML Keyboard"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="HTML Preformatted"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="HTML Sample"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="HTML Typewriter"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="HTML Variable"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Normal Table"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="annotation subject"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="No List"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Outline List 1"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Outline List 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Outline List 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Simple 1"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Simple 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Simple 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Classic 1"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Classic 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Classic 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Classic 4"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Colorful 1"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Colorful 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Colorful 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Columns 1"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Columns 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Columns 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Columns 4"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Columns 5"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Grid 1"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Grid 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Grid 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Grid 4"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Grid 5"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Grid 6"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Grid 7"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Grid 8"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table List 1"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table List 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table List 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table List 4"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table List 5"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table List 6"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table List 7"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table List 8"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table 3D effects 1"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table 3D effects 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table 3D effects 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Contemporary"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Elegant"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Professional"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Subtle 1"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Subtle 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Web 1"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Web 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Web 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Balloon Text"/>
  <w:LsdException Locked="false" Priority="39" Name="Table Grid"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Theme"/>
  <w:LsdException Locked="false" SemiHidden="true" Name="Placeholder Text"/>
  <w:LsdException Locked="false" Priority="1" QFormat="true" Name="No Spacing"/>
  <w:LsdException Locked="false" Priority="60" Name="Light Shading"/>
  <w:LsdException Locked="false" Priority="61" Name="Light List"/>
  <w:LsdException Locked="false" Priority="62" Name="Light Grid"/>
  <w:LsdException Locked="false" Priority="63" Name="Medium Shading 1"/>
  <w:LsdException Locked="false" Priority="64" Name="Medium Shading 2"/>
  <w:LsdException Locked="false" Priority="65" Name="Medium List 1"/>
  <w:LsdException Locked="false" Priority="66" Name="Medium List 2"/>
  <w:LsdException Locked="false" Priority="67" Name="Medium Grid 1"/>
  <w:LsdException Locked="false" Priority="68" Name="Medium Grid 2"/>
  <w:LsdException Locked="false" Priority="69" Name="Medium Grid 3"/>
  <w:LsdException Locked="false" Priority="70" Name="Dark List"/>
  <w:LsdException Locked="false" Priority="71" Name="Colorful Shading"/>
  <w:LsdException Locked="false" Priority="72" Name="Colorful List"/>
  <w:LsdException Locked="false" Priority="73" Name="Colorful Grid"/>
  <w:LsdException Locked="false" Priority="60" Name="Light Shading Accent 1"/>
  <w:LsdException Locked="false" Priority="61" Name="Light List Accent 1"/>
  <w:LsdException Locked="false" Priority="62" Name="Light Grid Accent 1"/>
  <w:LsdException Locked="false" Priority="63" Name="Medium Shading 1 Accent 1"/>
  <w:LsdException Locked="false" Priority="64" Name="Medium Shading 2 Accent 1"/>
  <w:LsdException Locked="false" Priority="65" Name="Medium List 1 Accent 1"/>
  <w:LsdException Locked="false" SemiHidden="true" Name="Revision"/>
  <w:LsdException Locked="false" Priority="34" QFormat="true"
   Name="List Paragraph"/>
  <w:LsdException Locked="false" Priority="29" QFormat="true" Name="Quote"/>
  <w:LsdException Locked="false" Priority="30" QFormat="true"
   Name="Intense Quote"/>
  <w:LsdException Locked="false" Priority="66" Name="Medium List 2 Accent 1"/>
  <w:LsdException Locked="false" Priority="67" Name="Medium Grid 1 Accent 1"/>
  <w:LsdException Locked="false" Priority="68" Name="Medium Grid 2 Accent 1"/>
  <w:LsdException Locked="false" Priority="69" Name="Medium Grid 3 Accent 1"/>
  <w:LsdException Locked="false" Priority="70" Name="Dark List Accent 1"/>
  <w:LsdException Locked="false" Priority="71" Name="Colorful Shading Accent 1"/>
  <w:LsdException Locked="false" Priority="72" Name="Colorful List Accent 1"/>
  <w:LsdException Locked="false" Priority="73" Name="Colorful Grid Accent 1"/>
  <w:LsdException Locked="false" Priority="60" Name="Light Shading Accent 2"/>
  <w:LsdException Locked="false" Priority="61" Name="Light List Accent 2"/>
  <w:LsdException Locked="false" Priority="62" Name="Light Grid Accent 2"/>
  <w:LsdException Locked="false" Priority="63" Name="Medium Shading 1 Accent 2"/>
  <w:LsdException Locked="false" Priority="64" Name="Medium Shading 2 Accent 2"/>
  <w:LsdException Locked="false" Priority="65" Name="Medium List 1 Accent 2"/>
  <w:LsdException Locked="false" Priority="66" Name="Medium List 2 Accent 2"/>
  <w:LsdException Locked="false" Priority="67" Name="Medium Grid 1 Accent 2"/>
  <w:LsdException Locked="false" Priority="68" Name="Medium Grid 2 Accent 2"/>
  <w:LsdException Locked="false" Priority="69" Name="Medium Grid 3 Accent 2"/>
  <w:LsdException Locked="false" Priority="70" Name="Dark List Accent 2"/>
  <w:LsdException Locked="false" Priority="71" Name="Colorful Shading Accent 2"/>
  <w:LsdException Locked="false" Priority="72" Name="Colorful List Accent 2"/>
  <w:LsdException Locked="false" Priority="73" Name="Colorful Grid Accent 2"/>
  <w:LsdException Locked="false" Priority="60" Name="Light Shading Accent 3"/>
  <w:LsdException Locked="false" Priority="61" Name="Light List Accent 3"/>
  <w:LsdException Locked="false" Priority="62" Name="Light Grid Accent 3"/>
  <w:LsdException Locked="false" Priority="63" Name="Medium Shading 1 Accent 3"/>
  <w:LsdException Locked="false" Priority="64" Name="Medium Shading 2 Accent 3"/>
  <w:LsdException Locked="false" Priority="65" Name="Medium List 1 Accent 3"/>
  <w:LsdException Locked="false" Priority="66" Name="Medium List 2 Accent 3"/>
  <w:LsdException Locked="false" Priority="67" Name="Medium Grid 1 Accent 3"/>
  <w:LsdException Locked="false" Priority="68" Name="Medium Grid 2 Accent 3"/>
  <w:LsdException Locked="false" Priority="69" Name="Medium Grid 3 Accent 3"/>
  <w:LsdException Locked="false" Priority="70" Name="Dark List Accent 3"/>
  <w:LsdException Locked="false" Priority="71" Name="Colorful Shading Accent 3"/>
  <w:LsdException Locked="false" Priority="72" Name="Colorful List Accent 3"/>
  <w:LsdException Locked="false" Priority="73" Name="Colorful Grid Accent 3"/>
  <w:LsdException Locked="false" Priority="60" Name="Light Shading Accent 4"/>
  <w:LsdException Locked="false" Priority="61" Name="Light List Accent 4"/>
  <w:LsdException Locked="false" Priority="62" Name="Light Grid Accent 4"/>
  <w:LsdException Locked="false" Priority="63" Name="Medium Shading 1 Accent 4"/>
  <w:LsdException Locked="false" Priority="64" Name="Medium Shading 2 Accent 4"/>
  <w:LsdException Locked="false" Priority="65" Name="Medium List 1 Accent 4"/>
  <w:LsdException Locked="false" Priority="66" Name="Medium List 2 Accent 4"/>
  <w:LsdException Locked="false" Priority="67" Name="Medium Grid 1 Accent 4"/>
  <w:LsdException Locked="false" Priority="68" Name="Medium Grid 2 Accent 4"/>
  <w:LsdException Locked="false" Priority="69" Name="Medium Grid 3 Accent 4"/>
  <w:LsdException Locked="false" Priority="70" Name="Dark List Accent 4"/>
  <w:LsdException Locked="false" Priority="71" Name="Colorful Shading Accent 4"/>
  <w:LsdException Locked="false" Priority="72" Name="Colorful List Accent 4"/>
  <w:LsdException Locked="false" Priority="73" Name="Colorful Grid Accent 4"/>
  <w:LsdException Locked="false" Priority="60" Name="Light Shading Accent 5"/>
  <w:LsdException Locked="false" Priority="61" Name="Light List Accent 5"/>
  <w:LsdException Locked="false" Priority="62" Name="Light Grid Accent 5"/>
  <w:LsdException Locked="false" Priority="63" Name="Medium Shading 1 Accent 5"/>
  <w:LsdException Locked="false" Priority="64" Name="Medium Shading 2 Accent 5"/>
  <w:LsdException Locked="false" Priority="65" Name="Medium List 1 Accent 5"/>
  <w:LsdException Locked="false" Priority="66" Name="Medium List 2 Accent 5"/>
  <w:LsdException Locked="false" Priority="67" Name="Medium Grid 1 Accent 5"/>
  <w:LsdException Locked="false" Priority="68" Name="Medium Grid 2 Accent 5"/>
  <w:LsdException Locked="false" Priority="69" Name="Medium Grid 3 Accent 5"/>
  <w:LsdException Locked="false" Priority="70" Name="Dark List Accent 5"/>
  <w:LsdException Locked="false" Priority="71" Name="Colorful Shading Accent 5"/>
  <w:LsdException Locked="false" Priority="72" Name="Colorful List Accent 5"/>
  <w:LsdException Locked="false" Priority="73" Name="Colorful Grid Accent 5"/>
  <w:LsdException Locked="false" Priority="60" Name="Light Shading Accent 6"/>
  <w:LsdException Locked="false" Priority="61" Name="Light List Accent 6"/>
  <w:LsdException Locked="false" Priority="62" Name="Light Grid Accent 6"/>
  <w:LsdException Locked="false" Priority="63" Name="Medium Shading 1 Accent 6"/>
  <w:LsdException Locked="false" Priority="64" Name="Medium Shading 2 Accent 6"/>
  <w:LsdException Locked="false" Priority="65" Name="Medium List 1 Accent 6"/>
  <w:LsdException Locked="false" Priority="66" Name="Medium List 2 Accent 6"/>
  <w:LsdException Locked="false" Priority="67" Name="Medium Grid 1 Accent 6"/>
  <w:LsdException Locked="false" Priority="68" Name="Medium Grid 2 Accent 6"/>
  <w:LsdException Locked="false" Priority="69" Name="Medium Grid 3 Accent 6"/>
  <w:LsdException Locked="false" Priority="70" Name="Dark List Accent 6"/>
  <w:LsdException Locked="false" Priority="71" Name="Colorful Shading Accent 6"/>
  <w:LsdException Locked="false" Priority="72" Name="Colorful List Accent 6"/>
  <w:LsdException Locked="false" Priority="73" Name="Colorful Grid Accent 6"/>
  <w:LsdException Locked="false" Priority="19" QFormat="true"
   Name="Subtle Emphasis"/>
  <w:LsdException Locked="false" Priority="21" QFormat="true"
   Name="Intense Emphasis"/>
  <w:LsdException Locked="false" Priority="31" QFormat="true"
   Name="Subtle Reference"/>
  <w:LsdException Locked="false" Priority="32" QFormat="true"
   Name="Intense Reference"/>
  <w:LsdException Locked="false" Priority="33" QFormat="true" Name="Book Title"/>
  <w:LsdException Locked="false" Priority="37" SemiHidden="true"
   UnhideWhenUsed="true" Name="Bibliography"/>
  <w:LsdException Locked="false" Priority="39" SemiHidden="true"
   UnhideWhenUsed="true" QFormat="true" Name="TOC Heading"/>
  <w:LsdException Locked="false" Priority="41" Name="Plain Table 1"/>
  <w:LsdException Locked="false" Priority="42" Name="Plain Table 2"/>
  <w:LsdException Locked="false" Priority="43" Name="Plain Table 3"/>
  <w:LsdException Locked="false" Priority="44" Name="Plain Table 4"/>
  <w:LsdException Locked="false" Priority="45" Name="Plain Table 5"/>
  <w:LsdException Locked="false" Priority="40" Name="Grid Table Light"/>
  <w:LsdException Locked="false" Priority="46" Name="Grid Table 1 Light"/>
  <w:LsdException Locked="false" Priority="47" Name="Grid Table 2"/>
  <w:LsdException Locked="false" Priority="48" Name="Grid Table 3"/>
  <w:LsdException Locked="false" Priority="49" Name="Grid Table 4"/>
  <w:LsdException Locked="false" Priority="50" Name="Grid Table 5 Dark"/>
  <w:LsdException Locked="false" Priority="51" Name="Grid Table 6 Colorful"/>
  <w:LsdException Locked="false" Priority="52" Name="Grid Table 7 Colorful"/>
  <w:LsdException Locked="false" Priority="46"
   Name="Grid Table 1 Light Accent 1"/>
  <w:LsdException Locked="false" Priority="47" Name="Grid Table 2 Accent 1"/>
  <w:LsdException Locked="false" Priority="48" Name="Grid Table 3 Accent 1"/>
  <w:LsdException Locked="false" Priority="49" Name="Grid Table 4 Accent 1"/>
  <w:LsdException Locked="false" Priority="50" Name="Grid Table 5 Dark Accent 1"/>
  <w:LsdException Locked="false" Priority="51"
   Name="Grid Table 6 Colorful Accent 1"/>
  <w:LsdException Locked="false" Priority="52"
   Name="Grid Table 7 Colorful Accent 1"/>
  <w:LsdException Locked="false" Priority="46"
   Name="Grid Table 1 Light Accent 2"/>
  <w:LsdException Locked="false" Priority="47" Name="Grid Table 2 Accent 2"/>
  <w:LsdException Locked="false" Priority="48" Name="Grid Table 3 Accent 2"/>
  <w:LsdException Locked="false" Priority="49" Name="Grid Table 4 Accent 2"/>
  <w:LsdException Locked="false" Priority="50" Name="Grid Table 5 Dark Accent 2"/>
  <w:LsdException Locked="false" Priority="51"
   Name="Grid Table 6 Colorful Accent 2"/>
  <w:LsdException Locked="false" Priority="52"
   Name="Grid Table 7 Colorful Accent 2"/>
  <w:LsdException Locked="false" Priority="46"
   Name="Grid Table 1 Light Accent 3"/>
  <w:LsdException Locked="false" Priority="47" Name="Grid Table 2 Accent 3"/>
  <w:LsdException Locked="false" Priority="48" Name="Grid Table 3 Accent 3"/>
  <w:LsdException Locked="false" Priority="49" Name="Grid Table 4 Accent 3"/>
  <w:LsdException Locked="false" Priority="50" Name="Grid Table 5 Dark Accent 3"/>
  <w:LsdException Locked="false" Priority="51"
   Name="Grid Table 6 Colorful Accent 3"/>
  <w:LsdException Locked="false" Priority="52"
   Name="Grid Table 7 Colorful Accent 3"/>
  <w:LsdException Locked="false" Priority="46"
   Name="Grid Table 1 Light Accent 4"/>
  <w:LsdException Locked="false" Priority="47" Name="Grid Table 2 Accent 4"/>
  <w:LsdException Locked="false" Priority="48" Name="Grid Table 3 Accent 4"/>
  <w:LsdException Locked="false" Priority="49" Name="Grid Table 4 Accent 4"/>
  <w:LsdException Locked="false" Priority="50" Name="Grid Table 5 Dark Accent 4"/>
  <w:LsdException Locked="false" Priority="51"
   Name="Grid Table 6 Colorful Accent 4"/>
  <w:LsdException Locked="false" Priority="52"
   Name="Grid Table 7 Colorful Accent 4"/>
  <w:LsdException Locked="false" Priority="46"
   Name="Grid Table 1 Light Accent 5"/>
  <w:LsdException Locked="false" Priority="47" Name="Grid Table 2 Accent 5"/>
  <w:LsdException Locked="false" Priority="48" Name="Grid Table 3 Accent 5"/>
  <w:LsdException Locked="false" Priority="49" Name="Grid Table 4 Accent 5"/>
  <w:LsdException Locked="false" Priority="50" Name="Grid Table 5 Dark Accent 5"/>
  <w:LsdException Locked="false" Priority="51"
   Name="Grid Table 6 Colorful Accent 5"/>
  <w:LsdException Locked="false" Priority="52"
   Name="Grid Table 7 Colorful Accent 5"/>
  <w:LsdException Locked="false" Priority="46"
   Name="Grid Table 1 Light Accent 6"/>
  <w:LsdException Locked="false" Priority="47" Name="Grid Table 2 Accent 6"/>
  <w:LsdException Locked="false" Priority="48" Name="Grid Table 3 Accent 6"/>
  <w:LsdException Locked="false" Priority="49" Name="Grid Table 4 Accent 6"/>
  <w:LsdException Locked="false" Priority="50" Name="Grid Table 5 Dark Accent 6"/>
  <w:LsdException Locked="false" Priority="51"
   Name="Grid Table 6 Colorful Accent 6"/>
  <w:LsdException Locked="false" Priority="52"
   Name="Grid Table 7 Colorful Accent 6"/>
  <w:LsdException Locked="false" Priority="46" Name="List Table 1 Light"/>
  <w:LsdException Locked="false" Priority="47" Name="List Table 2"/>
  <w:LsdException Locked="false" Priority="48" Name="List Table 3"/>
  <w:LsdException Locked="false" Priority="49" Name="List Table 4"/>
  <w:LsdException Locked="false" Priority="50" Name="List Table 5 Dark"/>
  <w:LsdException Locked="false" Priority="51" Name="List Table 6 Colorful"/>
  <w:LsdException Locked="false" Priority="52" Name="List Table 7 Colorful"/>
  <w:LsdException Locked="false" Priority="46"
   Name="List Table 1 Light Accent 1"/>
  <w:LsdException Locked="false" Priority="47" Name="List Table 2 Accent 1"/>
  <w:LsdException Locked="false" Priority="48" Name="List Table 3 Accent 1"/>
  <w:LsdException Locked="false" Priority="49" Name="List Table 4 Accent 1"/>
  <w:LsdException Locked="false" Priority="50" Name="List Table 5 Dark Accent 1"/>
  <w:LsdException Locked="false" Priority="51"
   Name="List Table 6 Colorful Accent 1"/>
  <w:LsdException Locked="false" Priority="52"
   Name="List Table 7 Colorful Accent 1"/>
  <w:LsdException Locked="false" Priority="46"
   Name="List Table 1 Light Accent 2"/>
  <w:LsdException Locked="false" Priority="47" Name="List Table 2 Accent 2"/>
  <w:LsdException Locked="false" Priority="48" Name="List Table 3 Accent 2"/>
  <w:LsdException Locked="false" Priority="49" Name="List Table 4 Accent 2"/>
  <w:LsdException Locked="false" Priority="50" Name="List Table 5 Dark Accent 2"/>
  <w:LsdException Locked="false" Priority="51"
   Name="List Table 6 Colorful Accent 2"/>
  <w:LsdException Locked="false" Priority="52"
   Name="List Table 7 Colorful Accent 2"/>
  <w:LsdException Locked="false" Priority="46"
   Name="List Table 1 Light Accent 3"/>
  <w:LsdException Locked="false" Priority="47" Name="List Table 2 Accent 3"/>
  <w:LsdException Locked="false" Priority="48" Name="List Table 3 Accent 3"/>
  <w:LsdException Locked="false" Priority="49" Name="List Table 4 Accent 3"/>
  <w:LsdException Locked="false" Priority="50" Name="List Table 5 Dark Accent 3"/>
  <w:LsdException Locked="false" Priority="51"
   Name="List Table 6 Colorful Accent 3"/>
  <w:LsdException Locked="false" Priority="52"
   Name="List Table 7 Colorful Accent 3"/>
  <w:LsdException Locked="false" Priority="46"
   Name="List Table 1 Light Accent 4"/>
  <w:LsdException Locked="false" Priority="47" Name="List Table 2 Accent 4"/>
  <w:LsdException Locked="false" Priority="48" Name="List Table 3 Accent 4"/>
  <w:LsdException Locked="false" Priority="49" Name="List Table 4 Accent 4"/>
  <w:LsdException Locked="false" Priority="50" Name="List Table 5 Dark Accent 4"/>
  <w:LsdException Locked="false" Priority="51"
   Name="List Table 6 Colorful Accent 4"/>
  <w:LsdException Locked="false" Priority="52"
   Name="List Table 7 Colorful Accent 4"/>
  <w:LsdException Locked="false" Priority="46"
   Name="List Table 1 Light Accent 5"/>
  <w:LsdException Locked="false" Priority="47" Name="List Table 2 Accent 5"/>
  <w:LsdException Locked="false" Priority="48" Name="List Table 3 Accent 5"/>
  <w:LsdException Locked="false" Priority="49" Name="List Table 4 Accent 5"/>
  <w:LsdException Locked="false" Priority="50" Name="List Table 5 Dark Accent 5"/>
  <w:LsdException Locked="false" Priority="51"
   Name="List Table 6 Colorful Accent 5"/>
  <w:LsdException Locked="false" Priority="52"
   Name="List Table 7 Colorful Accent 5"/>
  <w:LsdException Locked="false" Priority="46"
   Name="List Table 1 Light Accent 6"/>
  <w:LsdException Locked="false" Priority="47" Name="List Table 2 Accent 6"/>
  <w:LsdException Locked="false" Priority="48" Name="List Table 3 Accent 6"/>
  <w:LsdException Locked="false" Priority="49" Name="List Table 4 Accent 6"/>
  <w:LsdException Locked="false" Priority="50" Name="List Table 5 Dark Accent 6"/>
  <w:LsdException Locked="false" Priority="51"
   Name="List Table 6 Colorful Accent 6"/>
  <w:LsdException Locked="false" Priority="52"
   Name="List Table 7 Colorful Accent 6"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Mention"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Smart Hyperlink"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Hashtag"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Unresolved Mention"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Smart Link"/>
 </w:LatentStyles>
</xml><![endif]-->
<style>
<!--
 /* Font Definitions */
 @font-face
	{font-family:"Cambria Math";
	panose-1:2 4 5 3 5 4 6 3 2 4;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:-536869121 1107305727 33554432 0 415 0;}
@font-face
	{font-family:DengXian;
	panose-1:2 1 6 0 3 1 1 1 1 1;
	mso-font-alt:\7B49\7EBF;
	mso-font-charset:134;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:-1610612033 953122042 22 0 262159 0;}
@font-face
	{font-family:Aptos;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:536871559 3 0 0 415 0;}
@font-face
	{font-family:"Segoe UI Emoji";
	panose-1:2 11 5 2 4 2 4 2 2 3;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:3 33554432 134217728 0 1 0;}
@font-face
	{font-family:"Segoe UI Symbol";
	panose-1:2 11 5 2 4 2 4 2 2 3;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-2147483165 302055407 262144 0 1 0;}
@font-face
	{font-family:"\@DengXian";
	panose-1:2 1 6 0 3 1 1 1 1 1;
	mso-font-charset:134;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:-1610612033 953122042 22 0 262159 0;}
 /* Style Definitions */
 p.MsoNormal, li.MsoNormal, div.MsoNormal
	{mso-style-unhide:no;
	mso-style-qformat:yes;
	mso-style-parent:"";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:0in;
	line-height:115%;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Aptos",sans-serif;
	mso-ascii-font-family:Aptos;
	mso-ascii-theme-font:minor-latin;
	mso-fareast-font-family:DengXian;
	mso-fareast-theme-font:minor-fareast;
	mso-hansi-font-family:Aptos;
	mso-hansi-theme-font:minor-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:minor-bidi;
	mso-font-kerning:1.0pt;
	mso-ligatures:standardcontextual;}
h1
	{mso-style-priority:9;
	mso-style-unhide:no;
	mso-style-qformat:yes;
	mso-style-link:"Heading 1 Char";
	mso-style-next:Normal;
	margin-top:.25in;
	margin-right:0in;
	margin-bottom:4.0pt;
	margin-left:0in;
	line-height:115%;
	mso-pagination:widow-orphan lines-together;
	page-break-after:avoid;
	mso-outline-level:1;
	font-size:20.0pt;
	font-family:"Aptos Display",sans-serif;
	mso-ascii-font-family:"Aptos Display";
	mso-ascii-theme-font:major-latin;
	mso-fareast-font-family:"DengXian Light";
	mso-fareast-theme-font:major-fareast;
	mso-hansi-font-family:"Aptos Display";
	mso-hansi-theme-font:major-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:major-bidi;
	color:#0F4761;
	mso-themecolor:accent1;
	mso-themeshade:191;
	mso-font-kerning:1.0pt;
	mso-ligatures:standardcontextual;
	font-weight:normal;}
h2
	{mso-style-noshow:yes;
	mso-style-priority:9;
	mso-style-qformat:yes;
	mso-style-link:"Heading 2 Char";
	mso-style-next:Normal;
	margin-top:8.0pt;
	margin-right:0in;
	margin-bottom:4.0pt;
	margin-left:0in;
	line-height:115%;
	mso-pagination:widow-orphan lines-together;
	page-break-after:avoid;
	mso-outline-level:2;
	font-size:16.0pt;
	font-family:"Aptos Display",sans-serif;
	mso-ascii-font-family:"Aptos Display";
	mso-ascii-theme-font:major-latin;
	mso-fareast-font-family:"DengXian Light";
	mso-fareast-theme-font:major-fareast;
	mso-hansi-font-family:"Aptos Display";
	mso-hansi-theme-font:major-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:major-bidi;
	color:#0F4761;
	mso-themecolor:accent1;
	mso-themeshade:191;
	mso-font-kerning:1.0pt;
	mso-ligatures:standardcontextual;
	font-weight:normal;}
h3
	{mso-style-noshow:yes;
	mso-style-priority:9;
	mso-style-qformat:yes;
	mso-style-link:"Heading 3 Char";
	mso-style-next:Normal;
	margin-top:8.0pt;
	margin-right:0in;
	margin-bottom:4.0pt;
	margin-left:0in;
	line-height:115%;
	mso-pagination:widow-orphan lines-together;
	page-break-after:avoid;
	mso-outline-level:3;
	font-size:14.0pt;
	font-family:"Aptos",sans-serif;
	mso-ascii-font-family:Aptos;
	mso-ascii-theme-font:minor-latin;
	mso-fareast-font-family:"DengXian Light";
	mso-fareast-theme-font:major-fareast;
	mso-hansi-font-family:Aptos;
	mso-hansi-theme-font:minor-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:major-bidi;
	color:#0F4761;
	mso-themecolor:accent1;
	mso-themeshade:191;
	mso-font-kerning:1.0pt;
	mso-ligatures:standardcontextual;
	font-weight:normal;}
h4
	{mso-style-noshow:yes;
	mso-style-priority:9;
	mso-style-qformat:yes;
	mso-style-link:"Heading 4 Char";
	mso-style-next:Normal;
	margin-top:4.0pt;
	margin-right:0in;
	margin-bottom:2.0pt;
	margin-left:0in;
	line-height:115%;
	mso-pagination:widow-orphan lines-together;
	page-break-after:avoid;
	mso-outline-level:4;
	font-size:12.0pt;
	font-family:"Aptos",sans-serif;
	mso-ascii-font-family:Aptos;
	mso-ascii-theme-font:minor-latin;
	mso-fareast-font-family:"DengXian Light";
	mso-fareast-theme-font:major-fareast;
	mso-hansi-font-family:Aptos;
	mso-hansi-theme-font:minor-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:major-bidi;
	color:#0F4761;
	mso-themecolor:accent1;
	mso-themeshade:191;
	mso-font-kerning:1.0pt;
	mso-ligatures:standardcontextual;
	font-weight:normal;
	font-style:italic;}
h5
	{mso-style-noshow:yes;
	mso-style-priority:9;
	mso-style-qformat:yes;
	mso-style-link:"Heading 5 Char";
	mso-style-next:Normal;
	margin-top:4.0pt;
	margin-right:0in;
	margin-bottom:2.0pt;
	margin-left:0in;
	line-height:115%;
	mso-pagination:widow-orphan lines-together;
	page-break-after:avoid;
	mso-outline-level:5;
	font-size:12.0pt;
	font-family:"Aptos",sans-serif;
	mso-ascii-font-family:Aptos;
	mso-ascii-theme-font:minor-latin;
	mso-fareast-font-family:"DengXian Light";
	mso-fareast-theme-font:major-fareast;
	mso-hansi-font-family:Aptos;
	mso-hansi-theme-font:minor-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:major-bidi;
	color:#0F4761;
	mso-themecolor:accent1;
	mso-themeshade:191;
	mso-font-kerning:1.0pt;
	mso-ligatures:standardcontextual;
	font-weight:normal;}
h6
	{mso-style-noshow:yes;
	mso-style-priority:9;
	mso-style-qformat:yes;
	mso-style-link:"Heading 6 Char";
	mso-style-next:Normal;
	margin-top:2.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	line-height:115%;
	mso-pagination:widow-orphan lines-together;
	page-break-after:avoid;
	mso-outline-level:6;
	font-size:12.0pt;
	font-family:"Aptos",sans-serif;
	mso-ascii-font-family:Aptos;
	mso-ascii-theme-font:minor-latin;
	mso-fareast-font-family:"DengXian Light";
	mso-fareast-theme-font:major-fareast;
	mso-hansi-font-family:Aptos;
	mso-hansi-theme-font:minor-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:major-bidi;
	color:#595959;
	mso-themecolor:text1;
	mso-themetint:166;
	mso-font-kerning:1.0pt;
	mso-ligatures:standardcontextual;
	font-weight:normal;
	font-style:italic;}
p.MsoHeading7, li.MsoHeading7, div.MsoHeading7
	{mso-style-noshow:yes;
	mso-style-priority:9;
	mso-style-qformat:yes;
	mso-style-link:"Heading 7 Char";
	mso-style-next:Normal;
	margin-top:2.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	line-height:115%;
	mso-pagination:widow-orphan lines-together;
	page-break-after:avoid;
	mso-outline-level:7;
	font-size:12.0pt;
	font-family:"Aptos",sans-serif;
	mso-ascii-font-family:Aptos;
	mso-ascii-theme-font:minor-latin;
	mso-fareast-font-family:"DengXian Light";
	mso-fareast-theme-font:major-fareast;
	mso-hansi-font-family:Aptos;
	mso-hansi-theme-font:minor-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:major-bidi;
	color:#595959;
	mso-themecolor:text1;
	mso-themetint:166;
	mso-font-kerning:1.0pt;
	mso-ligatures:standardcontextual;}
p.MsoHeading8, li.MsoHeading8, div.MsoHeading8
	{mso-style-noshow:yes;
	mso-style-priority:9;
	mso-style-qformat:yes;
	mso-style-link:"Heading 8 Char";
	mso-style-next:Normal;
	margin:0in;
	line-height:115%;
	mso-pagination:widow-orphan lines-together;
	page-break-after:avoid;
	mso-outline-level:8;
	font-size:12.0pt;
	font-family:"Aptos",sans-serif;
	mso-ascii-font-family:Aptos;
	mso-ascii-theme-font:minor-latin;
	mso-fareast-font-family:"DengXian Light";
	mso-fareast-theme-font:major-fareast;
	mso-hansi-font-family:Aptos;
	mso-hansi-theme-font:minor-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:major-bidi;
	color:#272727;
	mso-themecolor:text1;
	mso-themetint:216;
	mso-font-kerning:1.0pt;
	mso-ligatures:standardcontextual;
	font-style:italic;}
p.MsoHeading9, li.MsoHeading9, div.MsoHeading9
	{mso-style-noshow:yes;
	mso-style-priority:9;
	mso-style-qformat:yes;
	mso-style-link:"Heading 9 Char";
	mso-style-next:Normal;
	margin:0in;
	line-height:115%;
	mso-pagination:widow-orphan lines-together;
	page-break-after:avoid;
	mso-outline-level:9;
	font-size:12.0pt;
	font-family:"Aptos",sans-serif;
	mso-ascii-font-family:Aptos;
	mso-ascii-theme-font:minor-latin;
	mso-fareast-font-family:"DengXian Light";
	mso-fareast-theme-font:major-fareast;
	mso-hansi-font-family:Aptos;
	mso-hansi-theme-font:minor-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:major-bidi;
	color:#272727;
	mso-themecolor:text1;
	mso-themetint:216;
	mso-font-kerning:1.0pt;
	mso-ligatures:standardcontextual;}
p.MsoTitle, li.MsoTitle, div.MsoTitle
	{mso-style-priority:10;
	mso-style-unhide:no;
	mso-style-qformat:yes;
	mso-style-link:"Title Char";
	mso-style-next:Normal;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:4.0pt;
	margin-left:0in;
	mso-add-space:auto;
	mso-pagination:widow-orphan;
	font-size:28.0pt;
	font-family:"Aptos Display",sans-serif;
	mso-ascii-font-family:"Aptos Display";
	mso-ascii-theme-font:major-latin;
	mso-fareast-font-family:"DengXian Light";
	mso-fareast-theme-font:major-fareast;
	mso-hansi-font-family:"Aptos Display";
	mso-hansi-theme-font:major-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:major-bidi;
	letter-spacing:-.5pt;
	mso-font-kerning:14.0pt;
	mso-ligatures:standardcontextual;}
p.MsoTitleCxSpFirst, li.MsoTitleCxSpFirst, div.MsoTitleCxSpFirst
	{mso-style-priority:10;
	mso-style-unhide:no;
	mso-style-qformat:yes;
	mso-style-link:"Title Char";
	mso-style-next:Normal;
	mso-style-type:export-only;
	margin:0in;
	mso-add-space:auto;
	mso-pagination:widow-orphan;
	font-size:28.0pt;
	font-family:"Aptos Display",sans-serif;
	mso-ascii-font-family:"Aptos Display";
	mso-ascii-theme-font:major-latin;
	mso-fareast-font-family:"DengXian Light";
	mso-fareast-theme-font:major-fareast;
	mso-hansi-font-family:"Aptos Display";
	mso-hansi-theme-font:major-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:major-bidi;
	letter-spacing:-.5pt;
	mso-font-kerning:14.0pt;
	mso-ligatures:standardcontextual;}
p.MsoTitleCxSpMiddle, li.MsoTitleCxSpMiddle, div.MsoTitleCxSpMiddle
	{mso-style-priority:10;
	mso-style-unhide:no;
	mso-style-qformat:yes;
	mso-style-link:"Title Char";
	mso-style-next:Normal;
	mso-style-type:export-only;
	margin:0in;
	mso-add-space:auto;
	mso-pagination:widow-orphan;
	font-size:28.0pt;
	font-family:"Aptos Display",sans-serif;
	mso-ascii-font-family:"Aptos Display";
	mso-ascii-theme-font:major-latin;
	mso-fareast-font-family:"DengXian Light";
	mso-fareast-theme-font:major-fareast;
	mso-hansi-font-family:"Aptos Display";
	mso-hansi-theme-font:major-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:major-bidi;
	letter-spacing:-.5pt;
	mso-font-kerning:14.0pt;
	mso-ligatures:standardcontextual;}
p.MsoTitleCxSpLast, li.MsoTitleCxSpLast, div.MsoTitleCxSpLast
	{mso-style-priority:10;
	mso-style-unhide:no;
	mso-style-qformat:yes;
	mso-style-link:"Title Char";
	mso-style-next:Normal;
	mso-style-type:export-only;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:4.0pt;
	margin-left:0in;
	mso-add-space:auto;
	mso-pagination:widow-orphan;
	font-size:28.0pt;
	font-family:"Aptos Display",sans-serif;
	mso-ascii-font-family:"Aptos Display";
	mso-ascii-theme-font:major-latin;
	mso-fareast-font-family:"DengXian Light";
	mso-fareast-theme-font:major-fareast;
	mso-hansi-font-family:"Aptos Display";
	mso-hansi-theme-font:major-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:major-bidi;
	letter-spacing:-.5pt;
	mso-font-kerning:14.0pt;
	mso-ligatures:standardcontextual;}
p.MsoSubtitle, li.MsoSubtitle, div.MsoSubtitle
	{mso-style-priority:11;
	mso-style-unhide:no;
	mso-style-qformat:yes;
	mso-style-link:"Subtitle Char";
	mso-style-next:Normal;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:0in;
	line-height:115%;
	mso-pagination:widow-orphan;
	font-size:14.0pt;
	font-family:"Aptos",sans-serif;
	mso-ascii-font-family:Aptos;
	mso-ascii-theme-font:minor-latin;
	mso-fareast-font-family:"DengXian Light";
	mso-fareast-theme-font:major-fareast;
	mso-hansi-font-family:Aptos;
	mso-hansi-theme-font:minor-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:major-bidi;
	color:#595959;
	mso-themecolor:text1;
	mso-themetint:166;
	letter-spacing:.75pt;
	mso-font-kerning:1.0pt;
	mso-ligatures:standardcontextual;}
p.MsoListParagraph, li.MsoListParagraph, div.MsoListParagraph
	{mso-style-priority:34;
	mso-style-unhide:no;
	mso-style-qformat:yes;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:.5in;
	mso-add-space:auto;
	line-height:115%;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Aptos",sans-serif;
	mso-ascii-font-family:Aptos;
	mso-ascii-theme-font:minor-latin;
	mso-fareast-font-family:DengXian;
	mso-fareast-theme-font:minor-fareast;
	mso-hansi-font-family:Aptos;
	mso-hansi-theme-font:minor-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:minor-bidi;
	mso-font-kerning:1.0pt;
	mso-ligatures:standardcontextual;}
p.MsoListParagraphCxSpFirst, li.MsoListParagraphCxSpFirst, div.MsoListParagraphCxSpFirst
	{mso-style-priority:34;
	mso-style-unhide:no;
	mso-style-qformat:yes;
	mso-style-type:export-only;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	mso-add-space:auto;
	line-height:115%;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Aptos",sans-serif;
	mso-ascii-font-family:Aptos;
	mso-ascii-theme-font:minor-latin;
	mso-fareast-font-family:DengXian;
	mso-fareast-theme-font:minor-fareast;
	mso-hansi-font-family:Aptos;
	mso-hansi-theme-font:minor-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:minor-bidi;
	mso-font-kerning:1.0pt;
	mso-ligatures:standardcontextual;}
p.MsoListParagraphCxSpMiddle, li.MsoListParagraphCxSpMiddle, div.MsoListParagraphCxSpMiddle
	{mso-style-priority:34;
	mso-style-unhide:no;
	mso-style-qformat:yes;
	mso-style-type:export-only;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	mso-add-space:auto;
	line-height:115%;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Aptos",sans-serif;
	mso-ascii-font-family:Aptos;
	mso-ascii-theme-font:minor-latin;
	mso-fareast-font-family:DengXian;
	mso-fareast-theme-font:minor-fareast;
	mso-hansi-font-family:Aptos;
	mso-hansi-theme-font:minor-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:minor-bidi;
	mso-font-kerning:1.0pt;
	mso-ligatures:standardcontextual;}
p.MsoListParagraphCxSpLast, li.MsoListParagraphCxSpLast, div.MsoListParagraphCxSpLast
	{mso-style-priority:34;
	mso-style-unhide:no;
	mso-style-qformat:yes;
	mso-style-type:export-only;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:.5in;
	mso-add-space:auto;
	line-height:115%;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Aptos",sans-serif;
	mso-ascii-font-family:Aptos;
	mso-ascii-theme-font:minor-latin;
	mso-fareast-font-family:DengXian;
	mso-fareast-theme-font:minor-fareast;
	mso-hansi-font-family:Aptos;
	mso-hansi-theme-font:minor-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:minor-bidi;
	mso-font-kerning:1.0pt;
	mso-ligatures:standardcontextual;}
p.MsoQuote, li.MsoQuote, div.MsoQuote
	{mso-style-priority:29;
	mso-style-unhide:no;
	mso-style-qformat:yes;
	mso-style-link:"Quote Char";
	mso-style-next:Normal;
	margin-top:8.0pt;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:0in;
	text-align:center;
	line-height:115%;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Aptos",sans-serif;
	mso-ascii-font-family:Aptos;
	mso-ascii-theme-font:minor-latin;
	mso-fareast-font-family:DengXian;
	mso-fareast-theme-font:minor-fareast;
	mso-hansi-font-family:Aptos;
	mso-hansi-theme-font:minor-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:minor-bidi;
	color:#404040;
	mso-themecolor:text1;
	mso-themetint:191;
	mso-font-kerning:1.0pt;
	mso-ligatures:standardcontextual;
	font-style:italic;}
p.MsoIntenseQuote, li.MsoIntenseQuote, div.MsoIntenseQuote
	{mso-style-priority:30;
	mso-style-unhide:no;
	mso-style-qformat:yes;
	mso-style-link:"Intense Quote Char";
	mso-style-next:Normal;
	margin-top:.25in;
	margin-right:.6in;
	margin-bottom:.25in;
	margin-left:.6in;
	text-align:center;
	line-height:115%;
	mso-pagination:widow-orphan;
	border:none;
	mso-border-top-alt:solid #0F4761 .5pt;
	mso-border-top-themecolor:accent1;
	mso-border-top-themeshade:191;
	mso-border-bottom-alt:solid #0F4761 .5pt;
	mso-border-bottom-themecolor:accent1;
	mso-border-bottom-themeshade:191;
	padding:0in;
	mso-padding-alt:10.0pt 0in 10.0pt 0in;
	font-size:12.0pt;
	font-family:"Aptos",sans-serif;
	mso-ascii-font-family:Aptos;
	mso-ascii-theme-font:minor-latin;
	mso-fareast-font-family:DengXian;
	mso-fareast-theme-font:minor-fareast;
	mso-hansi-font-family:Aptos;
	mso-hansi-theme-font:minor-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:minor-bidi;
	color:#0F4761;
	mso-themecolor:accent1;
	mso-themeshade:191;
	mso-font-kerning:1.0pt;
	mso-ligatures:standardcontextual;
	font-style:italic;}
span.MsoIntenseEmphasis
	{mso-style-priority:21;
	mso-style-unhide:no;
	mso-style-qformat:yes;
	color:#0F4761;
	mso-themecolor:accent1;
	mso-themeshade:191;
	font-style:italic;}
span.MsoIntenseReference
	{mso-style-priority:32;
	mso-style-unhide:no;
	mso-style-qformat:yes;
	font-variant:small-caps;
	color:#0F4761;
	mso-themecolor:accent1;
	mso-themeshade:191;
	letter-spacing:.25pt;
	font-weight:bold;}
span.Heading1Char
	{mso-style-name:"Heading 1 Char";
	mso-style-priority:9;
	mso-style-unhide:no;
	mso-style-locked:yes;
	mso-style-link:"Heading 1";
	mso-ansi-font-size:20.0pt;
	mso-bidi-font-size:20.0pt;
	font-family:"Aptos Display",sans-serif;
	mso-ascii-font-family:"Aptos Display";
	mso-ascii-theme-font:major-latin;
	mso-fareast-font-family:"DengXian Light";
	mso-fareast-theme-font:major-fareast;
	mso-hansi-font-family:"Aptos Display";
	mso-hansi-theme-font:major-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:major-bidi;
	color:#0F4761;
	mso-themecolor:accent1;
	mso-themeshade:191;}
span.Heading2Char
	{mso-style-name:"Heading 2 Char";
	mso-style-noshow:yes;
	mso-style-priority:9;
	mso-style-unhide:no;
	mso-style-locked:yes;
	mso-style-link:"Heading 2";
	mso-ansi-font-size:16.0pt;
	mso-bidi-font-size:16.0pt;
	font-family:"Aptos Display",sans-serif;
	mso-ascii-font-family:"Aptos Display";
	mso-ascii-theme-font:major-latin;
	mso-fareast-font-family:"DengXian Light";
	mso-fareast-theme-font:major-fareast;
	mso-hansi-font-family:"Aptos Display";
	mso-hansi-theme-font:major-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:major-bidi;
	color:#0F4761;
	mso-themecolor:accent1;
	mso-themeshade:191;}
span.Heading3Char
	{mso-style-name:"Heading 3 Char";
	mso-style-noshow:yes;
	mso-style-priority:9;
	mso-style-unhide:no;
	mso-style-locked:yes;
	mso-style-link:"Heading 3";
	mso-ansi-font-size:14.0pt;
	mso-bidi-font-size:14.0pt;
	font-family:"DengXian Light";
	mso-fareast-font-family:"DengXian Light";
	mso-fareast-theme-font:major-fareast;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:major-bidi;
	color:#0F4761;
	mso-themecolor:accent1;
	mso-themeshade:191;}
span.Heading4Char
	{mso-style-name:"Heading 4 Char";
	mso-style-noshow:yes;
	mso-style-priority:9;
	mso-style-unhide:no;
	mso-style-locked:yes;
	mso-style-link:"Heading 4";
	font-family:"DengXian Light";
	mso-fareast-font-family:"DengXian Light";
	mso-fareast-theme-font:major-fareast;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:major-bidi;
	color:#0F4761;
	mso-themecolor:accent1;
	mso-themeshade:191;
	font-style:italic;}
span.Heading5Char
	{mso-style-name:"Heading 5 Char";
	mso-style-noshow:yes;
	mso-style-priority:9;
	mso-style-unhide:no;
	mso-style-locked:yes;
	mso-style-link:"Heading 5";
	font-family:"DengXian Light";
	mso-fareast-font-family:"DengXian Light";
	mso-fareast-theme-font:major-fareast;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:major-bidi;
	color:#0F4761;
	mso-themecolor:accent1;
	mso-themeshade:191;}
span.Heading6Char
	{mso-style-name:"Heading 6 Char";
	mso-style-noshow:yes;
	mso-style-priority:9;
	mso-style-unhide:no;
	mso-style-locked:yes;
	mso-style-link:"Heading 6";
	font-family:"DengXian Light";
	mso-fareast-font-family:"DengXian Light";
	mso-fareast-theme-font:major-fareast;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:major-bidi;
	color:#595959;
	mso-themecolor:text1;
	mso-themetint:166;
	font-style:italic;}
span.Heading7Char
	{mso-style-name:"Heading 7 Char";
	mso-style-noshow:yes;
	mso-style-priority:9;
	mso-style-unhide:no;
	mso-style-locked:yes;
	mso-style-link:"Heading 7";
	font-family:"DengXian Light";
	mso-fareast-font-family:"DengXian Light";
	mso-fareast-theme-font:major-fareast;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:major-bidi;
	color:#595959;
	mso-themecolor:text1;
	mso-themetint:166;}
span.Heading8Char
	{mso-style-name:"Heading 8 Char";
	mso-style-noshow:yes;
	mso-style-priority:9;
	mso-style-unhide:no;
	mso-style-locked:yes;
	mso-style-link:"Heading 8";
	font-family:"DengXian Light";
	mso-fareast-font-family:"DengXian Light";
	mso-fareast-theme-font:major-fareast;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:major-bidi;
	color:#272727;
	mso-themecolor:text1;
	mso-themetint:216;
	font-style:italic;}
span.Heading9Char
	{mso-style-name:"Heading 9 Char";
	mso-style-noshow:yes;
	mso-style-priority:9;
	mso-style-unhide:no;
	mso-style-locked:yes;
	mso-style-link:"Heading 9";
	font-family:"DengXian Light";
	mso-fareast-font-family:"DengXian Light";
	mso-fareast-theme-font:major-fareast;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:major-bidi;
	color:#272727;
	mso-themecolor:text1;
	mso-themetint:216;}
span.TitleChar
	{mso-style-name:"Title Char";
	mso-style-priority:10;
	mso-style-unhide:no;
	mso-style-locked:yes;
	mso-style-link:Title;
	mso-ansi-font-size:28.0pt;
	mso-bidi-font-size:28.0pt;
	font-family:"Aptos Display",sans-serif;
	mso-ascii-font-family:"Aptos Display";
	mso-ascii-theme-font:major-latin;
	mso-fareast-font-family:"DengXian Light";
	mso-fareast-theme-font:major-fareast;
	mso-hansi-font-family:"Aptos Display";
	mso-hansi-theme-font:major-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:major-bidi;
	letter-spacing:-.5pt;
	mso-font-kerning:14.0pt;}
span.SubtitleChar
	{mso-style-name:"Subtitle Char";
	mso-style-priority:11;
	mso-style-unhide:no;
	mso-style-locked:yes;
	mso-style-link:Subtitle;
	mso-ansi-font-size:14.0pt;
	mso-bidi-font-size:14.0pt;
	font-family:"DengXian Light";
	mso-fareast-font-family:"DengXian Light";
	mso-fareast-theme-font:major-fareast;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:major-bidi;
	color:#595959;
	mso-themecolor:text1;
	mso-themetint:166;
	letter-spacing:.75pt;}
span.QuoteChar
	{mso-style-name:"Quote Char";
	mso-style-priority:29;
	mso-style-unhide:no;
	mso-style-locked:yes;
	mso-style-link:Quote;
	color:#404040;
	mso-themecolor:text1;
	mso-themetint:191;
	font-style:italic;}
span.IntenseQuoteChar
	{mso-style-name:"Intense Quote Char";
	mso-style-priority:30;
	mso-style-unhide:no;
	mso-style-locked:yes;
	mso-style-link:"Intense Quote";
	color:#0F4761;
	mso-themecolor:accent1;
	mso-themeshade:191;
	font-style:italic;}
span.GramE
	{mso-style-name:"";
	mso-gram-e:yes;}
.MsoChpDefault
	{mso-style-type:export-only;
	mso-default-props:yes;
	font-size:12.0pt;
	mso-ansi-font-size:12.0pt;
	mso-bidi-font-size:12.0pt;
	font-family:"Aptos",sans-serif;
	mso-ascii-font-family:Aptos;
	mso-ascii-theme-font:minor-latin;
	mso-fareast-font-family:DengXian;
	mso-fareast-theme-font:minor-fareast;
	mso-hansi-font-family:Aptos;
	mso-hansi-theme-font:minor-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:minor-bidi;}
.MsoPapDefault
	{mso-style-type:export-only;
	margin-bottom:8.0pt;
	line-height:115%;}
@page WordSection1
	{size:8.5in 11.0in;
	margin:1.0in 1.0in 1.0in 1.0in;
	mso-header-margin:.5in;
	mso-footer-margin:.5in;
	mso-paper-source:0;}
div.WordSection1
	{page:WordSection1;}
-->
</style>
<!--[if gte mso 10]>
<style>
 /* Style Definitions */
 table.MsoNormalTable
	{mso-style-name:"Table Normal";
	mso-tstyle-rowband-size:0;
	mso-tstyle-colband-size:0;
	mso-style-noshow:yes;
	mso-style-priority:99;
	mso-style-parent:"";
	mso-padding-alt:0in 5.4pt 0in 5.4pt;
	mso-para-margin-top:0in;
	mso-para-margin-right:0in;
	mso-para-margin-bottom:8.0pt;
	mso-para-margin-left:0in;
	line-height:115%;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Aptos",sans-serif;
	mso-ascii-font-family:Aptos;
	mso-ascii-theme-font:minor-latin;
	mso-hansi-font-family:Aptos;
	mso-hansi-theme-font:minor-latin;
	mso-font-kerning:1.0pt;
	mso-ligatures:standardcontextual;}
</style>
<![endif]--><!--[if gte mso 9]><xml>
 <o:shapedefaults v:ext="edit" spidmax="1026"/>
</xml><![endif]--><!--[if gte mso 9]><xml>
 <o:shapelayout v:ext="edit">
  <o:idmap v:ext="edit" data="1"/>
 </o:shapelayout></xml><![endif]-->
</head>

<body lang=EN-US style='tab-interval:.5in;word-wrap:break-word'>

<div class=WordSection1>

<p class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
line-height:normal;mso-outline-level:2'><b><span style='font-size:18.0pt;
font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-font-kerning:0pt;mso-ligatures:none'>Statistical Results Interpretation
Summary Table<o:p></o:p></span></b></p>

<table class=MsoNormalTable border=1 cellspacing=3 cellpadding=0
 style='mso-cellspacing:1.5pt;border:solid windowtext 1.0pt;mso-border-alt:
 solid windowtext .5pt;mso-yfti-tbllook:1184;mso-border-insideh:.5pt solid windowtext;
 mso-border-insidev:.5pt solid windowtext'>
 <thead>
  <tr style='mso-yfti-irow:0;mso-yfti-firstrow:yes'>
   <td style='border:solid windowtext 1.0pt;mso-border-alt:solid windowtext .5pt;
   padding:.75pt .75pt .75pt .75pt'>
   <p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
   line-height:normal'><b><span style='font-family:"Times New Roman",serif;
   mso-fareast-font-family:"Times New Roman";mso-font-kerning:0pt;mso-ligatures:
   none'>Category<o:p></o:p></span></b></p>
   </td>
   <td style='border:solid windowtext 1.0pt;mso-border-alt:solid windowtext .5pt;
   padding:.75pt .75pt .75pt .75pt'>
   <p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
   line-height:normal'><b><span style='font-family:"Times New Roman",serif;
   mso-fareast-font-family:"Times New Roman";mso-font-kerning:0pt;mso-ligatures:
   none'>Statistical Method / Measure<o:p></o:p></span></b></p>
   </td>
   <td style='border:solid windowtext 1.0pt;mso-border-alt:solid windowtext .5pt;
   padding:.75pt .75pt .75pt .75pt'>
   <p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
   line-height:normal'><b><span style='font-family:"Times New Roman",serif;
   mso-fareast-font-family:"Times New Roman";mso-font-kerning:0pt;mso-ligatures:
   none'>Results Statement<o:p></o:p></span></b></p>
   </td>
   <td style='border:solid windowtext 1.0pt;mso-border-alt:solid windowtext .5pt;
   padding:.75pt .75pt .75pt .75pt'>
   <p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
   line-height:normal'><b><span style='font-family:"Times New Roman",serif;
   mso-fareast-font-family:"Times New Roman";mso-font-kerning:0pt;mso-ligatures:
   none'>Clinical Interpretation of the Effect Estimate</span></b><b><span
   style='font-family:"Times New Roman",serif;mso-font-kerning:0pt;mso-ligatures:
   none'><o:p></o:p></span></b></p>
   </td>
  </tr>
 </thead>
 <tr style='mso-yfti-irow:1'>
  <td style='border:solid windowtext 1.0pt;mso-border-alt:solid windowtext .5pt;
  padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
  mso-font-kerning:0pt;mso-ligatures:none'>Descriptive statistics<o:p></o:p></span></p>
  </td>
  <td style='border:solid windowtext 1.0pt;mso-border-alt:solid windowtext .5pt;
  padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
  mso-font-kerning:0pt;mso-ligatures:none'>Mean  SD<o:p></o:p></span></p>
  </td>
  <td style='border:solid windowtext 1.0pt;mso-border-alt:solid windowtext .5pt;
  padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
  mso-font-kerning:0pt;mso-ligatures:none'>The mean age of patients with NSCLC
  was 63.4  9.8 years.<o:p></o:p></span></p>
  </td>
  <td style='border:solid windowtext 1.0pt;mso-border-alt:solid windowtext .5pt;
  padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
  mso-font-kerning:0pt;mso-ligatures:none'>The average patient age was 63.4
  years, with most individuals <b>falling within</b> approximately 10 years</span><span
  style='font-family:"Times New Roman",serif;mso-font-kerning:0pt;mso-ligatures:
  none'> </span><span style='font-family:"Times New Roman",serif;mso-fareast-font-family:
  "Times New Roman";mso-font-kerning:0pt;mso-ligatures:none'>around the mean.<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:2'>
  <td style='border:solid windowtext 1.0pt;mso-border-alt:solid windowtext .5pt;
  padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
  mso-font-kerning:0pt;mso-ligatures:none'>Descriptive statistics<o:p></o:p></span></p>
  </td>
  <td style='border:solid windowtext 1.0pt;mso-border-alt:solid windowtext .5pt;
  padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
  mso-font-kerning:0pt;mso-ligatures:none'>Median (IQR)<o:p></o:p></span></p>
  </td>
  <td style='border:solid windowtext 1.0pt;mso-border-alt:solid windowtext .5pt;
  padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
  mso-font-kerning:0pt;mso-ligatures:none'>The median follow-up time was 26
  months (IQR: 1641).<o:p></o:p></span></p>
  </td>
  <td style='border:solid windowtext 1.0pt;mso-border-alt:solid windowtext .5pt;
  padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
  mso-font-kerning:0pt;mso-ligatures:none'>A typical patient was followed for
  just over 26 months, with <b>most patients</b> having follow-up durations
  between approximately 1.5 and 3.5 years.</span><span style='font-family:"Times New Roman",serif;
  mso-font-kerning:0pt;mso-ligatures:none'> <o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:3'>
  <td style='border:solid windowtext 1.0pt;mso-border-alt:solid windowtext .5pt;
  padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
  mso-font-kerning:0pt;mso-ligatures:none'>Descriptive statistics<o:p></o:p></span></p>
  </td>
  <td style='border:solid windowtext 1.0pt;mso-border-alt:solid windowtext .5pt;
  padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
  mso-font-kerning:0pt;mso-ligatures:none'>n (%)<o:p></o:p></span></p>
  </td>
  <td style='border:solid windowtext 1.0pt;mso-border-alt:solid windowtext .5pt;
  padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
  mso-font-kerning:0pt;mso-ligatures:none'>Male patients <b>accounted for</b>
  61.2% (n = 184) of the cohort.<o:p></o:p></span></p>
  </td>
  <td style='border:solid windowtext 1.0pt;mso-border-alt:solid windowtext .5pt;
  padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
  mso-font-kerning:0pt;mso-ligatures:none'>Approximately 61</span><span
  style='font-family:"Times New Roman",serif;mso-font-kerning:0pt;mso-ligatures:
  none'>% </span><span style='font-family:"Times New Roman",serif;mso-fareast-font-family:
  "Times New Roman";mso-font-kerning:0pt;mso-ligatures:none'>patients in the
  study population were male.<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:4'>
  <td style='border:solid windowtext 1.0pt;mso-border-alt:solid windowtext .5pt;
  padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
  mso-font-kerning:0pt;mso-ligatures:none'>Baseline comparison<o:p></o:p></span></p>
  </td>
  <td style='border:solid windowtext 1.0pt;mso-border-alt:solid windowtext .5pt;
  padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
  mso-font-kerning:0pt;mso-ligatures:none'>t test<o:p></o:p></span></p>
  </td>
  <td style='border:solid windowtext 1.0pt;mso-border-alt:solid windowtext .5pt;
  padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
  mso-font-kerning:0pt;mso-ligatures:none'>There was no significant difference
  in age between the pembrolizumab and chemotherapy groups (63.1  9.6 vs 63.8
   10.1 years, P = 0.47).<o:p></o:p></span></p>
  </td>
  <td style='border:solid windowtext 1.0pt;mso-border-alt:solid windowtext .5pt;
  padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
  mso-font-kerning:0pt;mso-ligatures:none'>The mean age differed by
  approximately 0.7 years between groups, indicating <b>similar age
  distributions/ comparable age.</b> <o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:5'>
  <td style='border:solid windowtext 1.0pt;mso-border-alt:solid windowtext .5pt;
  padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
  mso-font-kerning:0pt;mso-ligatures:none'>Baseline comparison<o:p></o:p></span></p>
  </td>
  <td style='border:solid windowtext 1.0pt;mso-border-alt:solid windowtext .5pt;
  padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
  mso-font-kerning:0pt;mso-ligatures:none'>&#967; test<o:p></o:p></span></p>
  </td>
  <td style='border:solid windowtext 1.0pt;mso-border-alt:solid windowtext .5pt;
  padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
  mso-font-kerning:0pt;mso-ligatures:none'>PD-L1 expression levels were
  comparable between the two groups (&#967; = 1.82, P = 0.18).<o:p></o:p></span></p>
  </td>
  <td style='border:solid windowtext 1.0pt;mso-border-alt:solid windowtext .5pt;
  padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
  mso-font-kerning:0pt;mso-ligatures:none'>The distribution of PD-L1 expression<b>
  categories</b> was similar between treatment groups.<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:6'>
  <td style='border:solid windowtext 1.0pt;mso-border-alt:solid windowtext .5pt;
  padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
  mso-font-kerning:0pt;mso-ligatures:none'>Continuous outcome comparison<o:p></o:p></span></p>
  </td>
  <td style='border:solid windowtext 1.0pt;mso-border-alt:solid windowtext .5pt;
  padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
  mso-font-kerning:0pt;mso-ligatures:none'>Mean difference<o:p></o:p></span></p>
  </td>
  <td style='border:solid windowtext 1.0pt;mso-border-alt:solid windowtext .5pt;
  padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
  mso-font-kerning:0pt;mso-ligatures:none'>Pembrolizumab significantly <b>prolonged/increased</b>
  PFS compared with chemotherapy (8.4 vs 5.6 months; mean difference = 2.8
  months, P = 0.01).<o:p></o:p></span></p>
  </td>
  <td style='border:solid windowtext 1.0pt;mso-border-alt:solid windowtext .5pt;
  padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
  mso-font-kerning:0pt;mso-ligatures:none'>Compared with chemotherapy,
  pembrolizumab was associated with an average prolongation of PFS by 2.8
  months.<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:7'>
  <td style='border:solid windowtext 1.0pt;mso-border-alt:solid windowtext .5pt;
  padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
  mso-font-kerning:0pt;mso-ligatures:none'>Categorical outcome comparison<o:p></o:p></span></p>
  </td>
  <td style='border:solid windowtext 1.0pt;mso-border-alt:solid windowtext .5pt;
  padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
  mso-font-kerning:0pt;mso-ligatures:none'>Proportion<o:p></o:p></span></p>
  </td>
  <td style='border:solid windowtext 1.0pt;mso-border-alt:solid windowtext .5pt;
  padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
  mso-font-kerning:0pt;mso-ligatures:none'>The objective response rate was
  higher in the pembrolizumab group (38.5% vs 21.4%, P = 0.005).<o:p></o:p></span></p>
  </td>
  <td style='border:solid windowtext 1.0pt;mso-border-alt:solid windowtext .5pt;
  padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
  mso-font-kerning:0pt;mso-ligatures:none'>Compared with chemotherapy,
  pembrolizumab was associated with a higher likelihood of achieving an
  objective response<b>, with an absolute difference</b> of 17.1%.<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:8'>
  <td style='border:solid windowtext 1.0pt;mso-border-alt:solid windowtext .5pt;
  padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
  mso-font-kerning:0pt;mso-ligatures:none'>Correlation analysis<o:p></o:p></span></p>
  </td>
  <td style='border:solid windowtext 1.0pt;mso-border-alt:solid windowtext .5pt;
  padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
  mso-font-kerning:0pt;mso-ligatures:none'>Pearson correlation<o:p></o:p></span></p>
  </td>
  <td style='border:solid windowtext 1.0pt;mso-border-alt:solid windowtext .5pt;
  padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
  mso-font-kerning:0pt;mso-ligatures:none'>PD-L1 expression was moderately
  correlated with progression-free survival (r = 0.42, P &lt; 0.001).<o:p></o:p></span></p>
  </td>
  <td style='border:solid windowtext 1.0pt;mso-border-alt:solid windowtext .5pt;
  padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
  mso-font-kerning:0pt;mso-ligatures:none'>A correlation coefficient of 0.42
  indicates a moderate positive association, <b>with higher PD-L1 expression
  generally corresponding to longer PFS.</b><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:9'>
  <td style='border:solid windowtext 1.0pt;mso-border-alt:solid windowtext .5pt;
  padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
  mso-font-kerning:0pt;mso-ligatures:none'>Linear regression<o:p></o:p></span></p>
  </td>
  <td style='border:solid windowtext 1.0pt;mso-border-alt:solid windowtext .5pt;
  padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
  mso-font-kerning:0pt;mso-ligatures:none'>Linear regression (&#946;)<o:p></o:p></span></p>
  </td>
  <td style='border:solid windowtext 1.0pt;mso-border-alt:solid windowtext .5pt;
  padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
  mso-font-kerning:0pt;mso-ligatures:none'>Higher PD-L1 expression was
  associated with longer PFS (&#946; = 0.18 months per 10% increase, 95% CI:
  0.090.27, P &lt; 0.001).<o:p></o:p></span></p>
  </td>
  <td style='border:solid windowtext 1.0pt;mso-border-alt:solid windowtext .5pt;
  padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
  mso-font-kerning:0pt;mso-ligatures:none'>A &#946; of 0.18 indicates that <b>for
  every 10% increase</b> in PD-L1 expression, mean PFS increases by
  approximately 0.18 months.<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:10'>
  <td style='border:solid windowtext 1.0pt;mso-border-alt:solid windowtext .5pt;
  padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
  mso-font-kerning:0pt;mso-ligatures:none'>Logistic regression<o:p></o:p></span></p>
  </td>
  <td style='border:solid windowtext 1.0pt;mso-border-alt:solid windowtext .5pt;
  padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
  mso-font-kerning:0pt;mso-ligatures:none'>Odds ratio (OR)<o:p></o:p></span></p>
  </td>
  <td style='border:solid windowtext 1.0pt;mso-border-alt:solid windowtext .5pt;
  padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
  mso-font-kerning:0pt;mso-ligatures:none'>Pembrolizumab treatment was
  associated with a higher likelihood of objective response, (OR = 2.32, 95%
  CI: 1.453.71, P &lt; 0.001).<o:p></o:p></span></p>
  </td>
  <td style='border:solid windowtext 1.0pt;mso-border-alt:solid windowtext .5pt;
  padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
  mso-font-kerning:0pt;mso-ligatures:none'>An OR of 2.32 indicates that the
  odds of achieving an objective response <b>were approximately 2.3 times
  higher with pembrolizumab than</b> with chemotherapy.<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:11'>
  <td style='border:solid windowtext 1.0pt;mso-border-alt:solid windowtext .5pt;
  padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
  mso-font-kerning:0pt;mso-ligatures:none'>Survival analysis<o:p></o:p></span></p>
  </td>
  <td style='border:solid windowtext 1.0pt;mso-border-alt:solid windowtext .5pt;
  padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
  mso-font-kerning:0pt;mso-ligatures:none'>KaplanMeier<o:p></o:p></span></p>
  </td>
  <td style='border:solid windowtext 1.0pt;mso-border-alt:solid windowtext .5pt;
  padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
  mso-font-kerning:0pt;mso-ligatures:none'>KaplanMeier curves demonstrated
  improved PFS in the pembrolizumab group (median PFS: 8.4 vs 5.6 months).<o:p></o:p></span></p>
  </td>
  <td style='border:solid windowtext 1.0pt;mso-border-alt:solid windowtext .5pt;
  padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
  mso-font-kerning:0pt;mso-ligatures:none'>The median time to disease
  progression <b>was delayed by</b> approximately 2.8 months in the
  pembrolizumab group.<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:12'>
  <td style='border:solid windowtext 1.0pt;mso-border-alt:solid windowtext .5pt;
  padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
  mso-font-kerning:0pt;mso-ligatures:none'>Survival comparison<o:p></o:p></span></p>
  </td>
  <td style='border:solid windowtext 1.0pt;mso-border-alt:solid windowtext .5pt;
  padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
  mso-font-kerning:0pt;mso-ligatures:none'>Log-rank test<o:p></o:p></span></p>
  </td>
  <td style='border:solid windowtext 1.0pt;mso-border-alt:solid windowtext .5pt;
  padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
  mso-font-kerning:0pt;mso-ligatures:none'>PFS differed significantly between
  the two groups (log-rank P = 0.01).<o:p></o:p></span></p>
  </td>
  <td style='border:solid windowtext 1.0pt;mso-border-alt:solid windowtext .5pt;
  padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
  mso-font-kerning:0pt;mso-ligatures:none'>The timing of disease <b>progression
  over follow-up</b> differed between treatment groups.<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:13'>
  <td style='border:solid windowtext 1.0pt;mso-border-alt:solid windowtext .5pt;
  padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
  mso-font-kerning:0pt;mso-ligatures:none'>Cox regression<o:p></o:p></span></p>
  </td>
  <td style='border:solid windowtext 1.0pt;mso-border-alt:solid windowtext .5pt;
  padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
  mso-font-kerning:0pt;mso-ligatures:none'>Hazard ratio (HR)<o:p></o:p></span></p>
  </td>
  <td style='border:solid windowtext 1.0pt;mso-border-alt:solid windowtext .5pt;
  padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
  mso-font-kerning:0pt;mso-ligatures:none'>Pembrolizumab significantly reduced
  the risk of disease progression (HR = 0.65, 95% CI: 0.480.88, P = 0.004).<o:p></o:p></span></p>
  </td>
  <td style='border:solid windowtext 1.0pt;mso-border-alt:solid windowtext .5pt;
  padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
  mso-font-kerning:0pt;mso-ligatures:none'>An HR of 0.65 indicates that, at any
  given time point, the risk of disease progression was <b>approximately 35%
  lower with pembrolizumab.</b><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:14'>
  <td style='border:solid windowtext 1.0pt;mso-border-alt:solid windowtext .5pt;
  padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
  mso-font-kerning:0pt;mso-ligatures:none'>Multivariable analysis<o:p></o:p></span></p>
  </td>
  <td style='border:solid windowtext 1.0pt;mso-border-alt:solid windowtext .5pt;
  padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
  mso-font-kerning:0pt;mso-ligatures:none'>Adjusted Cox model<o:p></o:p></span></p>
  </td>
  <td style='border:solid windowtext 1.0pt;mso-border-alt:solid windowtext .5pt;
  padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
  mso-font-kerning:0pt;mso-ligatures:none'>Pembrolizumab remained an
  independent protective factor after adjustment (adjusted HR = 0.68, 95% CI:
  0.510.90, P = 0.01).<o:p></o:p></span></p>
  </td>
  <td style='border:solid windowtext 1.0pt;mso-border-alt:solid windowtext .5pt;
  padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><b><span
  style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
  mso-font-kerning:0pt;mso-ligatures:none'>After adjustment for covariates,</span></b><span
  style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
  mso-font-kerning:0pt;mso-ligatures:none'> the risk of disease progression
  remained approximately 32% lower in the pembrolizumab group.<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:15'>
  <td style='border:solid windowtext 1.0pt;mso-border-alt:solid windowtext .5pt;
  padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
  mso-font-kerning:0pt;mso-ligatures:none'>Subgroup analysis<o:p></o:p></span></p>
  </td>
  <td style='border:solid windowtext 1.0pt;mso-border-alt:solid windowtext .5pt;
  padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
  mso-font-kerning:0pt;mso-ligatures:none'>Subgroup analysis<o:p></o:p></span></p>
  </td>
  <td style='border:solid windowtext 1.0pt;mso-border-alt:solid windowtext .5pt;
  padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
  mso-font-kerning:0pt;mso-ligatures:none'>Consistent PFS benefit was observed
  across PD-L1 subgroups (P for interaction = 0.41).<o:p></o:p></span></p>
  </td>
  <td style='border:solid windowtext 1.0pt;mso-border-alt:solid windowtext .5pt;
  padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><b><span
  style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
  mso-font-kerning:0pt;mso-ligatures:none'>Similar magnitudes of risk reduction</span></b><span
  style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
  mso-font-kerning:0pt;mso-ligatures:none'> were observed across PD-L1
  subgroups.<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:16'>
  <td style='border:solid windowtext 1.0pt;mso-border-alt:solid windowtext .5pt;
  padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
  mso-font-kerning:0pt;mso-ligatures:none'>Interaction analysis<o:p></o:p></span></p>
  </td>
  <td style='border:solid windowtext 1.0pt;mso-border-alt:solid windowtext .5pt;
  padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
  mso-font-kerning:0pt;mso-ligatures:none'>Interaction test<o:p></o:p></span></p>
  </td>
  <td style='border:solid windowtext 1.0pt;mso-border-alt:solid windowtext .5pt;
  padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><b><span
  style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
  mso-font-kerning:0pt;mso-ligatures:none'>No significant interaction was
  observed</span></b><span style='font-family:"Times New Roman",serif;
  mso-fareast-font-family:"Times New Roman";mso-font-kerning:0pt;mso-ligatures:
  none'> between treatment and PD-L1 expression (P for interaction = 0.41).<o:p></o:p></span></p>
  </td>
  <td style='border:solid windowtext 1.0pt;mso-border-alt:solid windowtext .5pt;
  padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
  mso-font-kerning:0pt;mso-ligatures:none'>The effect size of pembrolizumab did
  not meaningfully differ <b>across PD-L1 levels.</b><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:17'>
  <td style='border:solid windowtext 1.0pt;mso-border-alt:solid windowtext .5pt;
  padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
  mso-font-kerning:0pt;mso-ligatures:none'>Sensitivity analysis<o:p></o:p></span></p>
  </td>
  <td style='border:solid windowtext 1.0pt;mso-border-alt:solid windowtext .5pt;
  padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
  mso-font-kerning:0pt;mso-ligatures:none'>Sensitivity analysis<o:p></o:p></span></p>
  </td>
  <td style='border:solid windowtext 1.0pt;mso-border-alt:solid windowtext .5pt;
  padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
  mso-font-kerning:0pt;mso-ligatures:none'>Results remained robust after
  excluding patients with follow-up &lt; 3 months (HR range: 0.620.70).<o:p></o:p></span></p>
  </td>
  <td style='border:solid windowtext 1.0pt;mso-border-alt:solid windowtext .5pt;
  padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
  mso-font-kerning:0pt;mso-ligatures:none'>Across sensitivity analyses, the
  estimated reduction in progression risk <b>ranged from approximately 30% to
  38%.</b><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:18'>
  <td style='border:solid windowtext 1.0pt;mso-border-alt:solid windowtext .5pt;
  padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
  mso-font-kerning:0pt;mso-ligatures:none'>Non-significant result<o:p></o:p></span></p>
  </td>
  <td style='border:solid windowtext 1.0pt;mso-border-alt:solid windowtext .5pt;
  padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
  mso-font-kerning:0pt;mso-ligatures:none'>Non-significant result<o:p></o:p></span></p>
  </td>
  <td style='border:solid windowtext 1.0pt;mso-border-alt:solid windowtext .5pt;
  padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
  mso-font-kerning:0pt;mso-ligatures:none'>OS was longer in the pembrolizumab
  group but not statistically significant (HR = 0.82, 95% CI: 0.641.05, P =
  0.09).<o:p></o:p></span></p>
  </td>
  <td style='border:solid windowtext 1.0pt;mso-border-alt:solid windowtext .5pt;
  padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
  mso-font-kerning:0pt;mso-ligatures:none'>Pembrolizumab was associated with a
  lower estimated risk of death (HR = 0.82), but <b>the confidence interval
  included <span class=GramE>unity</span> and the difference did not reach
  statistical significance.</b><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:19'>
  <td style='border:solid windowtext 1.0pt;mso-border-alt:solid windowtext .5pt;
  padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
  mso-font-kerning:0pt;mso-ligatures:none'>Trend<o:p></o:p></span></p>
  </td>
  <td style='border:solid windowtext 1.0pt;mso-border-alt:solid windowtext .5pt;
  padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
  mso-font-kerning:0pt;mso-ligatures:none'>Trend<o:p></o:p></span></p>
  </td>
  <td style='border:solid windowtext 1.0pt;mso-border-alt:solid windowtext .5pt;
  padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><b><span
  style='font-family:"Times New Roman",serif;mso-font-kerning:0pt;mso-ligatures:
  none'>A trend toward improved overall survival</span></b><span
  style='font-family:"Times New Roman",serif;mso-font-kerning:0pt;mso-ligatures:
  none'> was observed in the pembrolizumab group compared with the control
  group (median OS: 20.1 vs 17.3 months).<o:p></o:p></span></p>
  </td>
  <td style='border:solid windowtext 1.0pt;mso-border-alt:solid windowtext .5pt;
  padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
  mso-font-kerning:0pt;mso-ligatures:none'>The median overall survival was
  prolonged by approximately 2.8 months.<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:20'>
  <td style='border:solid windowtext 1.0pt;mso-border-alt:solid windowtext .5pt;
  padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
  mso-font-kerning:0pt;mso-ligatures:none'>Effect summary<o:p></o:p></span></p>
  </td>
  <td style='border:solid windowtext 1.0pt;mso-border-alt:solid windowtext .5pt;
  padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
  mso-font-kerning:0pt;mso-ligatures:none'>Effect estimate<o:p></o:p></span></p>
  </td>
  <td style='border:solid windowtext 1.0pt;mso-border-alt:solid windowtext .5pt;
  padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
  mso-font-kerning:0pt;mso-ligatures:none'>Pembrolizumab demonstrated a
  clinically meaningful treatment effect (HR &lt; 1 with a narrow 95% CI).<o:p></o:p></span></p>
  </td>
  <td style='border:solid windowtext 1.0pt;mso-border-alt:solid windowtext .5pt;
  padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
  mso-font-kerning:0pt;mso-ligatures:none'>An HR below 1 <b>with a relatively
  narrow confidence interval</b> suggests a stable estimate of reduced
  progression risk.<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:21'>
  <td style='border:solid windowtext 1.0pt;mso-border-alt:solid windowtext .5pt;
  padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
  mso-font-kerning:0pt;mso-ligatures:none'>Adjusted summary<o:p></o:p></span></p>
  </td>
  <td style='border:solid windowtext 1.0pt;mso-border-alt:solid windowtext .5pt;
  padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
  mso-font-kerning:0pt;mso-ligatures:none'>Multivariable model<o:p></o:p></span></p>
  </td>
  <td style='border:solid windowtext 1.0pt;mso-border-alt:solid windowtext .5pt;
  padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
  mso-font-kerning:0pt;mso-ligatures:none'>Pembrolizumab was independently
  associated with improved outcomes after adjustment (P &lt; 0.05).<o:p></o:p></span></p>
  </td>
  <td style='border:solid windowtext 1.0pt;mso-border-alt:solid windowtext .5pt;
  padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
  mso-font-kerning:0pt;mso-ligatures:none'>The estimated treatment effect <b>remained
  statistically different from the null</b> after covariate adjustment.<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:22'>
  <td style='border:solid windowtext 1.0pt;mso-border-alt:solid windowtext .5pt;
  padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
  mso-font-kerning:0pt;mso-ligatures:none'><o:p>&nbsp;</o:p></span></p>
  </td>
  <td style='border:solid windowtext 1.0pt;mso-border-alt:solid windowtext .5pt;
  padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
  mso-font-kerning:0pt;mso-ligatures:none'><o:p>&nbsp;</o:p></span></p>
  </td>
  <td style='border:solid windowtext 1.0pt;mso-border-alt:solid windowtext .5pt;
  padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
  mso-font-kerning:0pt;mso-ligatures:none'><span
  style='mso-spacerun:yes'></span><o:p></o:p></span></p>
  </td>
  <td style='border:solid windowtext 1.0pt;mso-border-alt:solid windowtext .5pt;
  padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
  mso-font-kerning:0pt;mso-ligatures:none'><o:p>&nbsp;</o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:23'>
  <td style='border:solid windowtext 1.0pt;mso-border-alt:solid windowtext .5pt;
  padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
  mso-font-kerning:0pt;mso-ligatures:none'>Risk comparison<o:p></o:p></span></p>
  </td>
  <td style='border:solid windowtext 1.0pt;mso-border-alt:solid windowtext .5pt;
  padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
  mso-font-kerning:0pt;mso-ligatures:none'>Relative Risk (RR)<o:p></o:p></span></p>
  </td>
  <td style='border:solid windowtext 1.0pt;mso-border-alt:solid windowtext .5pt;
  padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
  mso-font-kerning:0pt;mso-ligatures:none'>Pembrolizumab reduced the risk of
  disease progression <b>compared with chemotherapy</b> (RR = 0.72, 95% CI:
  0.600.86).<o:p></o:p></span></p>
  </td>
  <td style='border:solid windowtext 1.0pt;mso-border-alt:solid windowtext .5pt;
  padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
  mso-font-kerning:0pt;mso-ligatures:none'>An RR of 0.72 indicates that the
  probability of disease progression <b>was approximately 72% of that</b>
  observed with chemotherapy.<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:24'>
  <td style='border:solid windowtext 1.0pt;mso-border-alt:solid windowtext .5pt;
  padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
  mso-font-kerning:0pt;mso-ligatures:none'>Risk difference<o:p></o:p></span></p>
  </td>
  <td style='border:solid windowtext 1.0pt;mso-border-alt:solid windowtext .5pt;
  padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
  mso-font-kerning:0pt;mso-ligatures:none'>Absolute risk difference<o:p></o:p></span></p>
  </td>
  <td style='border:solid windowtext 1.0pt;mso-border-alt:solid windowtext .5pt;
  padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
  mso-font-kerning:0pt;mso-ligatures:none'>The absolute risk of progression was
  <b>18% lower in the pembrolizumab group.</b><o:p></o:p></span></p>
  </td>
  <td style='border:solid windowtext 1.0pt;mso-border-alt:solid windowtext .5pt;
  padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
  mso-font-kerning:0pt;mso-ligatures:none'>Out of every 100 patients treated,
  approximately 18 fewer experienced disease progression.<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:25'>
  <td style='border:solid windowtext 1.0pt;mso-border-alt:solid windowtext .5pt;
  padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
  mso-font-kerning:0pt;mso-ligatures:none'>Clinical relevance<o:p></o:p></span></p>
  </td>
  <td style='border:solid windowtext 1.0pt;mso-border-alt:solid windowtext .5pt;
  padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
  mso-font-kerning:0pt;mso-ligatures:none'>Number Needed to Treat (NNT)<o:p></o:p></span></p>
  </td>
  <td style='border:solid windowtext 1.0pt;mso-border-alt:solid windowtext .5pt;
  padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
  mso-font-kerning:0pt;mso-ligatures:none'>The NNT= 6 to prevent one
  progression event was 6.<o:p></o:p></span></p>
  </td>
  <td style='border:solid windowtext 1.0pt;mso-border-alt:solid windowtext .5pt;
  padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
  mso-font-kerning:0pt;mso-ligatures:none'>On average, treating 6 patients <b>prevents</b>
  one additional progression event.<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:26'>
  <td style='border:solid windowtext 1.0pt;mso-border-alt:solid windowtext .5pt;
  padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
  mso-font-kerning:0pt;mso-ligatures:none'>Survival analysis<o:p></o:p></span></p>
  </td>
  <td style='border:solid windowtext 1.0pt;mso-border-alt:solid windowtext .5pt;
  padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
  mso-font-kerning:0pt;mso-ligatures:none'>RMST difference<o:p></o:p></span></p>
  </td>
  <td style='border:solid windowtext 1.0pt;mso-border-alt:solid windowtext .5pt;
  padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  class=GramE><span style='font-family:"Times New Roman",serif;mso-fareast-font-family:
  "Times New Roman";mso-font-kerning:0pt;mso-ligatures:none'>RMST over 24
  months</span></span><span style='font-family:"Times New Roman",serif;
  mso-fareast-font-family:"Times New Roman";mso-font-kerning:0pt;mso-ligatures:
  none'> was longer in the pembrolizumab group (difference = 1.9 months, P =
  0.02).<o:p></o:p></span></p>
  </td>
  <td style='border:solid windowtext 1.0pt;mso-border-alt:solid windowtext .5pt;
  padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
  mso-font-kerning:0pt;mso-ligatures:none'>Within the first 24 months of
  follow-up, patients treated with pembrolizumab <b>experienced, on average,
  approximately 1.9 additional months </b>without progression compared with
  those receiving chemotherapy.<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:27'>
  <td style='border:solid windowtext 1.0pt;mso-border-alt:solid windowtext .5pt;
  padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
  mso-font-kerning:0pt;mso-ligatures:none'>Event frequency<o:p></o:p></span></p>
  </td>
  <td style='border:solid windowtext 1.0pt;mso-border-alt:solid windowtext .5pt;
  padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
  mso-font-kerning:0pt;mso-ligatures:none'>cumulative Incidence <span
  style='mso-spacerun:yes'></span><o:p></o:p></span></p>
  </td>
  <td style='border:solid windowtext 1.0pt;mso-border-alt:solid windowtext .5pt;
  padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
  mso-font-kerning:0pt;mso-ligatures:none'>Disease progression <b>occurred in
  42.3%</b> of the pembrolizumab group versus 58.1% of controls.<o:p></o:p></span></p>
  </td>
  <td style='border:solid windowtext 1.0pt;mso-border-alt:solid windowtext .5pt;
  padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
  mso-font-kerning:0pt;mso-ligatures:none'>The cumulative proportion of
  patients experiencing progression was reduced by approximately 15.8
  percentage points.<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:28'>
  <td style='border:solid windowtext 1.0pt;mso-border-alt:solid windowtext .5pt;
  padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
  mso-font-kerning:0pt;mso-ligatures:none'>Event rate<o:p></o:p></span></p>
  </td>
  <td style='border:solid windowtext 1.0pt;mso-border-alt:solid windowtext .5pt;
  padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
  mso-font-kerning:0pt;mso-ligatures:none'>Incidence rate<o:p></o:p></span></p>
  </td>
  <td valign=top style='border:solid windowtext 1.0pt;mso-border-alt:solid windowtext .5pt;
  padding:.75pt .75pt .75pt .75pt'>
  <table class=MsoNormalTable border=0 cellspacing=3 cellpadding=0
   style='mso-cellspacing:1.5pt;mso-yfti-tbllook:1184'>
   <tr style='mso-yfti-irow:0;mso-yfti-firstrow:yes;mso-yfti-lastrow:yes'>
    <td style='padding:.75pt .75pt .75pt .75pt'>
    <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
    style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
    mso-font-kerning:0pt;mso-ligatures:none'>The incidence rate of disease
    progression was 0.32 events per person-year in the pembrolizumab group
    compared with 0.48 events per person-year in the control group.<o:p></o:p></span></p>
    </td>
   </tr>
  </table>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
  mso-font-kerning:0pt;mso-ligatures:none'><o:p></o:p></span></p>
  </td>
  <td valign=top style='border:solid windowtext 1.0pt;mso-border-alt:solid windowtext .5pt;
  padding:.75pt .75pt .75pt .75pt'>
  <table class=MsoNormalTable border=0 cellspacing=3 cellpadding=0
   style='mso-cellspacing:1.5pt;mso-yfti-tbllook:1184'>
   <tr style='mso-yfti-irow:0;mso-yfti-firstrow:yes;mso-yfti-lastrow:yes'>
    <td style='padding:.75pt .75pt .75pt .75pt'>
    <p class=MsoNormal><span style='font-family:"Times New Roman",serif;
    mso-fareast-font-family:"Times New Roman";mso-font-kerning:0pt;mso-ligatures:
    none'>The incidence rate of disease progression was 0.32 events per
    person-year in the pembrolizumab group compared with 0.48 events per
    person-year in the control group.<o:p></o:p></span></p>
    </td>
   </tr>
  </table>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
  mso-font-kerning:0pt;mso-ligatures:none'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:29'>
  <td style='border:solid windowtext 1.0pt;mso-border-alt:solid windowtext .5pt;
  padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
  mso-font-kerning:0pt;mso-ligatures:none'>Regression model<o:p></o:p></span></p>
  </td>
  <td style='border:solid windowtext 1.0pt;mso-border-alt:solid windowtext .5pt;
  padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
  mso-font-kerning:0pt;mso-ligatures:none'>R<o:p></o:p></span></p>
  </td>
  <td style='border:solid windowtext 1.0pt;mso-border-alt:solid windowtext .5pt;
  padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
  mso-font-kerning:0pt;mso-ligatures:none'>The linear regression model <b>explained
  32% of the variance</b> in PFS (R = 0.32).<o:p></o:p></span></p>
  </td>
  <td style='border:solid windowtext 1.0pt;mso-border-alt:solid windowtext .5pt;
  padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
  mso-font-kerning:0pt;mso-ligatures:none'>Approximately 32% of the variability
  in PFS <b>was accounted for by the variables</b> included in the model.<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:30'>
  <td style='border:solid windowtext 1.0pt;mso-border-alt:solid windowtext .5pt;
  padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
  mso-font-kerning:0pt;mso-ligatures:none'>Model discrimination<o:p></o:p></span></p>
  </td>
  <td style='border:solid windowtext 1.0pt;mso-border-alt:solid windowtext .5pt;
  padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
  mso-font-kerning:0pt;mso-ligatures:none'>C-<span class=GramE>statistic</span>
  / AUC<o:p></o:p></span></p>
  </td>
  <td style='border:solid windowtext 1.0pt;mso-border-alt:solid windowtext .5pt;
  padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
  mso-font-kerning:0pt;mso-ligatures:none'>The model <b>demonstrated good
  discrimination</b> (C-statistic = 0.74).<o:p></o:p></span></p>
  </td>
  <td style='border:solid windowtext 1.0pt;mso-border-alt:solid windowtext .5pt;
  padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
  mso-font-kerning:0pt;mso-ligatures:none'>A C-statistic of 0.74 indicates a
  74% probability of correctly <b>distinguishing between</b> patients with and
  without progression.<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:31'>
  <td style='border:solid windowtext 1.0pt;mso-border-alt:solid windowtext .5pt;
  padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
  mso-font-kerning:0pt;mso-ligatures:none'>Uncertainty<o:p></o:p></span></p>
  </td>
  <td style='border:solid windowtext 1.0pt;mso-border-alt:solid windowtext .5pt;
  padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
  mso-font-kerning:0pt;mso-ligatures:none'>Standard Error (SE)<o:p></o:p></span></p>
  </td>
  <td style='border:solid windowtext 1.0pt;mso-border-alt:solid windowtext .5pt;
  padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
  mso-font-kerning:0pt;mso-ligatures:none'>The estimated mean difference had an
  SE of 0.6 months.<o:p></o:p></span></p>
  </td>
  <td style='border:solid windowtext 1.0pt;mso-border-alt:solid windowtext .5pt;
  padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><b><span
  style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
  mso-font-kerning:0pt;mso-ligatures:none'>The sampling variability of the
  estimated mean difference</span></b><span style='font-family:"Times New Roman",serif;
  mso-fareast-font-family:"Times New Roman";mso-font-kerning:0pt;mso-ligatures:
  none'> is approximately 0.6 months.<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:32'>
  <td style='border:solid windowtext 1.0pt;mso-border-alt:solid windowtext .5pt;
  padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
  mso-font-kerning:0pt;mso-ligatures:none'>Sensitivity analysis<o:p></o:p></span></p>
  </td>
  <td style='border:solid windowtext 1.0pt;mso-border-alt:solid windowtext .5pt;
  padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
  mso-font-kerning:0pt;mso-ligatures:none'>E-value<o:p></o:p></span></p>
  </td>
  <td style='border:solid windowtext 1.0pt;mso-border-alt:solid windowtext .5pt;
  padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
  mso-font-kerning:0pt;mso-ligatures:none'>The E-value for the observed HR was
  2.1.<o:p></o:p></span></p>
  </td>
  <td style='border:solid windowtext 1.0pt;mso-border-alt:solid windowtext .5pt;
  padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
  mso-font-kerning:0pt;mso-ligatures:none'>An unmeasured confounder would need
  to be associated with both treatment and outcome by a risk ratio of
  approximately 2.1 <b>to fully explain the observed effect.</b><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:33'>
  <td style='border:solid windowtext 1.0pt;mso-border-alt:solid windowtext .5pt;
  padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
  mso-font-kerning:0pt;mso-ligatures:none'>Multiple comparison<o:p></o:p></span></p>
  </td>
  <td style='border:solid windowtext 1.0pt;mso-border-alt:solid windowtext .5pt;
  padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
  mso-font-kerning:0pt;mso-ligatures:none'>Adjusted P value<o:p></o:p></span></p>
  </td>
  <td style='border:solid windowtext 1.0pt;mso-border-alt:solid windowtext .5pt;
  padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
  mso-font-kerning:0pt;mso-ligatures:none'>The association remained significant
  after multiplicity adjustment (adjusted P = 0.03).<o:p></o:p></span></p>
  </td>
  <td style='border:solid windowtext 1.0pt;mso-border-alt:solid windowtext .5pt;
  padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
  mso-font-kerning:0pt;mso-ligatures:none'>The effect estimate remained
  statistically distinguishable from the null after correction for multiple
  testing.<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:34;mso-yfti-lastrow:yes'>
  <td style='border:solid windowtext 1.0pt;mso-border-alt:solid windowtext .5pt;
  padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
  mso-font-kerning:0pt;mso-ligatures:none'>Model assumption<o:p></o:p></span></p>
  </td>
  <td style='border:solid windowtext 1.0pt;mso-border-alt:solid windowtext .5pt;
  padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
  mso-font-kerning:0pt;mso-ligatures:none'>PH assumption test<o:p></o:p></span></p>
  </td>
  <td style='border:solid windowtext 1.0pt;mso-border-alt:solid windowtext .5pt;
  padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
  mso-font-kerning:0pt;mso-ligatures:none'>The proportional hazards assumption <b>was
  not violated</b> (P = 0.62).<o:p></o:p></span></p>
  </td>
  <td style='border:solid windowtext 1.0pt;mso-border-alt:solid windowtext .5pt;
  padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
  style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
  mso-font-kerning:0pt;mso-ligatures:none'>The hazard ratio can be reasonably
  interpreted as approximately constant over time.<o:p></o:p></span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><o:p>&nbsp;</o:p></p>

<br clear=all style='mso-special-character:line-break;page-break-before:always'>

<p class=MsoNormal><o:p>&nbsp;</o:p></p>

<p class=MsoNormal><b>Results Section  Commonly Used Phrase <o:p></o:p></b></p>

<div class=MsoNormal align=center style='text-align:center'>

<hr size=2 width="100%" align=center>

</div>

<p class=MsoNormal>I. Study Population and Baseline Characteristics</p>

<table class=MsoNormalTable border=0 cellspacing=3 cellpadding=0
 style='mso-cellspacing:1.5pt;mso-yfti-tbllook:1184'>
 <thead>
  <tr style='mso-yfti-irow:0;mso-yfti-firstrow:yes'>
   <td style='padding:.75pt .75pt .75pt .75pt'>
   <p class=MsoNormal>Scenario</p>
   </td>
   <td style='padding:.75pt .75pt .75pt .75pt'>
   <p class=MsoNormal>Common Results Statements</p>
   </td>
  </tr>
 </thead>
 <tr style='mso-yfti-irow:1'>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal>Sample size</p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><b>A total of 302 patients with</b> nonsmall cell lung
  cancer <span class=GramE>were</span> included, <b>of whom</b> 156 received
  pembrolizumab.</p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:2'>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal>Baseline comparability</p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal>No statistically significant differences were observed
  between the two groups <b>with respect to</b> <b>age, sex</b>, disease stage,
  or smoking status.</p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:3'>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal>Baseline imbalance</p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal>Compared with the control group, <b>a higher proportion of
  patients with high PD-L1 expression was observed</b> in the pembrolizumab
  group (P = 0.03).</p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:4;mso-yfti-lastrow:yes'>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal>Missing data</p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal>A <b>total of 12 patients (4.0%) had missing values</b>
  for at least one clinical variable.</p>
  </td>
 </tr>
</table>

<div class=MsoNormal align=center style='text-align:center'>

<hr size=2 width="100%" align=center>

</div>

<p class=MsoNormal>II. Efficacy Outcomes</p>

<p class=MsoNormal>1&#65039;<span style='font-family:"Segoe UI Symbol",sans-serif;
mso-bidi-font-family:"Segoe UI Symbol"'>&#8419;</span> Survival Outcomes (PFS /
OS)</p>

<table class=MsoNormalTable border=0 cellspacing=3 cellpadding=0
 style='mso-cellspacing:1.5pt;mso-yfti-tbllook:1184'>
 <thead>
  <tr style='mso-yfti-irow:0;mso-yfti-firstrow:yes'>
   <td style='padding:.75pt .75pt .75pt .75pt'>
   <p class=MsoNormal>Scenario</p>
   </td>
   <td style='padding:.75pt .75pt .75pt .75pt'>
   <p class=MsoNormal>Common Results Statements</p>
   </td>
  </tr>
 </thead>
 <tr style='mso-yfti-irow:1'>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal>PFS description</p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal>The median progression-free survival in the pembrolizumab
  group was 8.4 months.</p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:2'>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal>OS description</p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal>The median overall survival in the overall cohort was 18.6
  months.</p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:3'>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal>Between-group comparison</p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal>Progression-free survival was significantly longer in the
  pembrolizumab group than in the control group (P = 0.01).</p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:4'>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal>KaplanMeier analysis</p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal>KaplanMeier survival curves demonstrated a significant
  difference in progression-free survival over follow-up between the two
  groups.</p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:5;mso-yfti-lastrow:yes'>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal>Risk reduction</p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal>Pembrolizumab treatment was associated with a
  significantly reduced risk of disease progression.</p>
  </td>
 </tr>
</table>

<div class=MsoNormal align=center style='text-align:center'>

<hr size=2 width="100%" align=center>

</div>

<p class=MsoNormal>2&#65039;<span style='font-family:"Segoe UI Symbol",sans-serif;
mso-bidi-font-family:"Segoe UI Symbol"'>&#8419;</span> Tumor Response (ORR /
DCR)</p>

<table class=MsoNormalTable border=0 cellspacing=3 cellpadding=0
 style='mso-cellspacing:1.5pt;mso-yfti-tbllook:1184'>
 <thead>
  <tr style='mso-yfti-irow:0;mso-yfti-firstrow:yes'>
   <td style='padding:.75pt .75pt .75pt .75pt'>
   <p class=MsoNormal>Scenario</p>
   </td>
   <td style='padding:.75pt .75pt .75pt .75pt'>
   <p class=MsoNormal>Common Results Statements</p>
   </td>
  </tr>
 </thead>
 <tr style='mso-yfti-irow:1'>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal>ORR</p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal>The objective response rate in the pembrolizumab group was
  38.5%.</p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:2'>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal>DCR</p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal>The disease control rate in the pembrolizumab group
  reached 64.2%.</p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:3'>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal>Between-group difference</p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal>Compared with the chemotherapy group, the objective
  response rate was significantly higher in the pembrolizumab group.</p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:4;mso-yfti-lastrow:yes'>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal>Subgroup response</p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal>Patients with high PD-L1 expression demonstrated a
  significantly higher objective response rate than those with low PD-L1
  expression.</p>
  </td>
 </tr>
</table>

<div class=MsoNormal align=center style='text-align:center'>

<hr size=2 width="100%" align=center>

</div>

<p class=MsoNormal>III. Safety Outcomes</p>

<table class=MsoNormalTable border=0 cellspacing=3 cellpadding=0
 style='mso-cellspacing:1.5pt;mso-yfti-tbllook:1184'>
 <thead>
  <tr style='mso-yfti-irow:0;mso-yfti-firstrow:yes'>
   <td style='padding:.75pt .75pt .75pt .75pt'>
   <p class=MsoNormal>Scenario</p>
   </td>
   <td style='padding:.75pt .75pt .75pt .75pt'>
   <p class=MsoNormal>Common Results Statements</p>
   </td>
  </tr>
 </thead>
 <tr style='mso-yfti-irow:1'>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal>Overall adverse events</p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal>At least one adverse event <b>occurred</b> <b>in 72.1% of
  patients receiving pembrolizumab.</b></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:2'>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal>Severe adverse events</p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal>Grade &#8805;3 adverse events were observed in 18.4% of
  patients.</p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:3'>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal>Between-group comparison</p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal>No statistically significant difference in the incidence
  of severe adverse events was observed between the two groups.</p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:4;mso-yfti-lastrow:yes'>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal>Immune-related events</p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal>The most common immune-related <b>adverse events</b> <b>included
  rash and thyroid dysfunction.</b></p>
  </td>
 </tr>
</table>

<div class=MsoNormal align=center style='text-align:center'>

<hr size=2 width="100%" align=center>

</div>

<p class=MsoNormal>IV. Correlation Analysis</p>

<table class=MsoNormalTable border=0 cellspacing=3 cellpadding=0
 style='mso-cellspacing:1.5pt;mso-yfti-tbllook:1184'>
 <thead>
  <tr style='mso-yfti-irow:0;mso-yfti-firstrow:yes'>
   <td style='padding:.75pt .75pt .75pt .75pt'>
   <p class=MsoNormal>Scenario</p>
   </td>
   <td style='padding:.75pt .75pt .75pt .75pt'>
   <p class=MsoNormal>Common Results Statements</p>
   </td>
  </tr>
 </thead>
 <tr style='mso-yfti-irow:1'>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal>Positive correlation</p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal>PD-L1 expression level was significantly positively
  correlated with progression-free survival.</p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:2'>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal>Negative correlation</p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal>Baseline tumor burden was negatively correlated with
  overall survival.</p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:3'>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal>Strength of correlation</p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal>The correlation <b>was of</b> <b>moderate strength</b> (r
  = 0.41).</p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:4;mso-yfti-lastrow:yes'>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal>Adjustment</p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal>The association remained after adjustment for age and
  disease stage.</p>
  </td>
 </tr>
</table>

<div class=MsoNormal align=center style='text-align:center'>

<hr size=2 width="100%" align=center>

</div>

<p class=MsoNormal>V. Regression Analysis</p>

<p class=MsoNormal>1&#65039;<span style='font-family:"Segoe UI Symbol",sans-serif;
mso-bidi-font-family:"Segoe UI Symbol"'>&#8419;</span> Univariate Analysis</p>

<table class=MsoNormalTable border=0 cellspacing=3 cellpadding=0
 style='mso-cellspacing:1.5pt;mso-yfti-tbllook:1184'>
 <thead>
  <tr style='mso-yfti-irow:0;mso-yfti-firstrow:yes'>
   <td style='padding:.75pt .75pt .75pt .75pt'>
   <p class=MsoNormal>Scenario</p>
   </td>
   <td style='padding:.75pt .75pt .75pt .75pt'>
   <p class=MsoNormal>Common Results Statements</p>
   </td>
  </tr>
 </thead>
 <tr style='mso-yfti-irow:1'>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal>Univariate Cox regression</p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal>In univariate Cox regression analysis, pembrolizumab
  treatment was significantly associated with a reduced risk of disease
  progression.</p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:2;mso-yfti-lastrow:yes'>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal>Univariate logistic regression</p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal>In univariate analysis, high PD-L1 expression was
  significantly associated with objective response.</p>
  </td>
 </tr>
</table>

<div class=MsoNormal align=center style='text-align:center'>

<hr size=2 width="100%" align=center>

</div>

<p class=MsoNormal>2&#65039;<span style='font-family:"Segoe UI Symbol",sans-serif;
mso-bidi-font-family:"Segoe UI Symbol"'>&#8419;</span> Multivariable Analysis
(Key Results)</p>

<table class=MsoNormalTable border=0 cellspacing=3 cellpadding=0
 style='mso-cellspacing:1.5pt;mso-yfti-tbllook:1184'>
 <thead>
  <tr style='mso-yfti-irow:0;mso-yfti-firstrow:yes'>
   <td style='padding:.75pt .75pt .75pt .75pt'>
   <p class=MsoNormal>Scenario</p>
   </td>
   <td style='padding:.75pt .75pt .75pt .75pt'>
   <p class=MsoNormal>Common Results Statements</p>
   </td>
  </tr>
 </thead>
 <tr style='mso-yfti-irow:1'>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal>Multivariable Cox regression</p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal>Multivariable Cox regression analysis demonstrated that
  pembrolizumab treatment was <b>an independent protective factor against
  disease progression.</b></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:2'>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal>Adjusted results</p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal>The association remained statistically significant after
  adjustment for age, sex, disease stage, and PD-L1 expression.</p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:3'>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal>Control of confounding</p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal>The results remained stable after controlling for
  potential confounding factors.</p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:4;mso-yfti-lastrow:yes'>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal>Model stability</p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><b>No significant multicollinearity was detected</b> among
  the variables included in the model.</p>
  </td>
 </tr>
</table>

<div class=MsoNormal align=center style='text-align:center'>

<hr size=2 width="100%" align=center>

</div>

<p class=MsoNormal>VI. Subgroup Analysis</p>

<table class=MsoNormalTable border=0 cellspacing=3 cellpadding=0
 style='mso-cellspacing:1.5pt;mso-yfti-tbllook:1184'>
 <thead>
  <tr style='mso-yfti-irow:0;mso-yfti-firstrow:yes'>
   <td style='padding:.75pt .75pt .75pt .75pt'>
   <p class=MsoNormal>Scenario</p>
   </td>
   <td style='padding:.75pt .75pt .75pt .75pt'>
   <p class=MsoNormal>Common Results Statements</p>
   </td>
  </tr>
 </thead>
 <tr style='mso-yfti-irow:1'>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal>Consistency across subgroups</p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal>Consistent treatment benefits of pembrolizumab were
  observed across all predefined subgroups.</p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:2'>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal>Interaction</p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal>No statistically significant interaction between treatment
  effect and subgroup variables was observed.</p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:3;mso-yfti-lastrow:yes'>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal>Specific population</p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal>The treatment benefit <b>appeared to be more pronounced</b>
  among patients with PD-L1 expression &#8805;50%.</p>
  </td>
 </tr>
</table>

<div class=MsoNormal align=center style='text-align:center'>

<hr size=2 width="100%" align=center>

</div>

<p class=MsoNormal>VII. Sensitivity Analysis</p>

<table class=MsoNormalTable border=0 cellspacing=3 cellpadding=0
 style='mso-cellspacing:1.5pt;mso-yfti-tbllook:1184'>
 <thead>
  <tr style='mso-yfti-irow:0;mso-yfti-firstrow:yes'>
   <td style='padding:.75pt .75pt .75pt .75pt'>
   <p class=MsoNormal>Scenario</p>
   </td>
   <td style='padding:.75pt .75pt .75pt .75pt'>
   <p class=MsoNormal>Common Results Statements</p>
   </td>
  </tr>
 </thead>
 <tr style='mso-yfti-irow:1'>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal>Purpose</p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal>Multiple sensitivity analyses were performed to assess the
  robustness of the findings.</p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:2'>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal>Exclusion analysis</p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal>After excluding patients with follow-up shorter than 3
  months, the main results <b>did not materially change.</b></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:3;mso-yfti-lastrow:yes'>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal>Alternative models</p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal>The primary conclusions <b>remained consistent</b> <b>when
  alternative statistical models were applied.</b></p>
  </td>
 </tr>
</table>

<div class=MsoNormal align=center style='text-align:center'>

<hr size=2 width="100%" align=center>

</div>

<p class=MsoNormal>VIII. Non-significant and Trend Results (Commonly Used)</p>

<table class=MsoNormalTable border=0 cellspacing=3 cellpadding=0
 style='mso-cellspacing:1.5pt;mso-yfti-tbllook:1184'>
 <thead>
  <tr style='mso-yfti-irow:0;mso-yfti-firstrow:yes'>
   <td style='padding:.75pt .75pt .75pt .75pt'>
   <p class=MsoNormal>Scenario</p>
   </td>
   <td style='padding:.75pt .75pt .75pt .75pt'>
   <p class=MsoNormal>Common Results Statements</p>
   </td>
  </tr>
 </thead>
 <tr style='mso-yfti-irow:1'>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal>Non-significant result</p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal>No statistically significant difference in overall
  survival was observed between the two groups.</p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:2'>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal>Trend</p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal>A trend toward longer overall survival was observed in the
  pembrolizumab group.</p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:3;mso-yfti-lastrow:yes'>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal>Explanation</p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal>This finding may <b>be partly attributable to</b> the
  limited sample size.</p>
  </td>
 </tr>
</table>

<div class=MsoNormal align=center style='text-align:center'>

<hr size=2 width="100%" align=center>

</div>

<p class=MsoNormal>IX. Summary Statements for the End of the Results Section</p>

<table class=MsoNormalTable border=0 cellspacing=3 cellpadding=0
 style='mso-cellspacing:1.5pt;mso-yfti-tbllook:1184'>
 <thead>
  <tr style='mso-yfti-irow:0;mso-yfti-firstrow:yes'>
   <td style='padding:.75pt .75pt .75pt .75pt'>
   <p class=MsoNormal>Scenario</p>
   </td>
   <td style='padding:.75pt .75pt .75pt .75pt'>
   <p class=MsoNormal>Common Results Statements</p>
   </td>
  </tr>
 </thead>
 <tr style='mso-yfti-irow:1'>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal>Overall summary</p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal>In summary, pembrolizumab demonstrated favorable efficacy
  and an acceptable safety profile in patients with nonsmall cell lung cancer.</p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:2'>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal>Emphasis</p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal>These findings support pembrolizumab as an effective
  treatment option for this patient population.</p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:3;mso-yfti-lastrow:yes'>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal>Transition</p>
  </td>
  <td style='padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal>These results <b>provide a basis for further investigation</b>
  of the long-term benefits of pembrolizumab.</p>
  </td>
 </tr>
</table>

<div class=MsoNormal align=center style='text-align:center'>

<hr size=2 width="100%" align=center>

</div>

<p class=MsoNormal><span style='font-family:"Segoe UI Emoji",sans-serif;
mso-bidi-font-family:"Segoe UI Emoji"'><span style='mso-spacerun:yes'></span></span></p>

</div>

</body>

</html>
